# Title: The spatiotemporal dynamics of microglia across the human lifespan

**Author list**: David A. Menassa<sup>1,2</sup>, Tim A.O. Muntslag<sup>1</sup>, Maria Martin-Estebané<sup>1</sup>, Liam Barry-Carroll<sup>1</sup>, Mark A. Chapman<sup>1</sup>, Istvan Adorjan<sup>3</sup>, Teadora Tyler<sup>3</sup>, Bethany Turnbull<sup>1</sup>, Matthew J.J. Rose-Zerilli<sup>4</sup>, James A.R. Nicoll<sup>5</sup>, Zeljka Krsnik<sup>6</sup>, Ivica Kostovic<sup>6</sup>, Diego Gomez-Nicola<sup>1\*</sup>

## Affiliations:

<sup>1</sup>School of Biological Sciences, University of Southampton, Southampton, United Kingdom

<sup>2</sup>Institute of Basic Medical Sciences, University of Oslo, Norway

<sup>3</sup>Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary

<sup>4</sup>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

<sup>5</sup>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

<sup>6</sup>Croatian Institute for Brain Research, University of Zagreb Medical School, Zagreb, Croatia

**Corresponding authors:** David A. Menassa (<u>david.menassa@queens.ox.ac.uk</u>) and Diego Gomez-Nicola (<u>d.gomez-nicola@soton.ac.uk</u>)

\*Lead contact: Diego Gomez-Nicola, Ph.D. School of Biological Sciences, University of Southampton. Southampton General Hospital, South Lab&Path Block, LD80C, MP840. Tremona Road. SO166YD, Southampton, United Kingdom. E-mail: <a href="mailto:d.gomez-nicola@soton.ac.uk">d.gomez-nicola@soton.ac.uk</a>

#### SUMMARY

Microglia, the brain's resident macrophages, shape neural development and are key neuroimmune hubs in the pathological signature of neurodevelopmental disorders. Despite their importance, microglial development has not been carefully examined in the human brain and most of our knowledge derives from rodents. We aimed to address this gap in knowledge, by establishing an extensive collection of 97 post-mortem tissues enabling quantitative, sexmatched, detailed analysis of microglia across the human lifespan. We identify the dynamics of these cells in the human telencephalon, describing waves in microglial density across gestation, infancy and childhood, controlled by a balance of proliferation and apoptosis, which track key neurodevelopmental milestones. These profound changes in microglia are also observed in bulk RNAseq and single-cell RNAseq datasets. This study provides detailed insight into the spatiotemporal dynamics of microglia across the human lifespan and serves as a foundation for elucidating how microglia contribute to shaping neurodevelopment in humans.

KEYWORDS: neurodevelopment, proliferation, apoptosis, RNAseq, single-cell RNAseq

## INTRODUCTION

Microglia are the main resident immune cells of the brain. During development, their roles include phagocytosis of neuronal precursors to restrict progenitor pool size (Cunningham et al., 2013); the modulation of forebrain wiring by guiding interneuron positioning (Squarzoni et al., 2014); the pruning of synapses (Paolicelli et al., 2011); and the formation and refinement of axonal tracts (Verney et al., 2010, Pont-Lezica et al., 2014, Squarzoni et al., 2014). In the adult, microglia retain key homeostatic functions, suppressing interneuron activation and modifying animal behaviour (Badimon et al., 2020); regulate hippocampal neurogenesis (Sierra et al., 2010); and drive inflammation in a disease context (Gomez-Nicola and Perry, 2015).

However, most of our knowledge of microglial developmental dynamics is derived from rodent studies. In the mouse, microglia originate from erythromyeloid progenitors in the extraembryonic yolk sac (YS) from E7.5 (Ginhoux et al., 2010). These progenitors begin populating the brain primordium at E9.5 and their phenotypic specification into microglia is defined by intrinsic and brain-specific transcriptional regulators (Lavin et al., 2014, Gosselin et al., 2014, Bennett et al., 2018). The entire microglial population is generated by expansion during embryonic life and the early postnatal developmental stages, followed by a transient postnatal selection phase (Askew et al., 2017, Réu et al., 2017). Under homeostatic conditions, the population is maintained throughout life by cycles of slow self-renewal estimated at approximately 0.69% per day (Askew et al., 2017).

Human microglial development has some similarities to mouse, as macrophages are detectable by 2-3 postconceptional weeks (pcw) in the blood islands of the extraembryonic YS (Nogales, 1993, Janossy et al., 1986, Popescu et al., 2019, Park et al., 2020), to later appear in the forebrain from the 3<sup>rd</sup> pcw (Verney et al., 2010, Menassa and Gomez-Nicola, 2018). A series of descriptive post-mortem studies collectively report on microglial proliferation in clusters appearing in the ventral telencephalon and diencephalon from the 4<sup>th</sup> pcw and continuing throughout fetal development (Monier et al., 2007, Monier et al., 2006, Verney et al., 2010). Recent single-cell transcriptomic studies suggest that microglial ontogenic pathways are conserved between human and mouse during embryonic development (Bian et al., 2020), with microglia progressing from an undifferentiated state towards a mature adult-like immunocompetent state from 11 pcw in humans (Kracht et al., 2020). The early arrival of microglia to the brain precedes the onset of pivotal processes of human cortical development such as neurogenesis, neuronal migration and gliogenesis (Menassa and Gomez-Nicola, 2018). In the adult, the population self-renews at a slow daily turnover rate which has been estimated at 0.08-2% (Askew et al., 2017, Réu et al., 2017). However, compared with the

mouse, we lack a deep understanding of microglial spatiotemporal dynamics during human development, largely due to the scarcity of developing tissues available for research.

We established an unprecedented collection of 97 post-mortem tissues (Fig 1) enabling quantitative, sex-matched, and detailed analysis of microglial dynamics across the human lifespan (3<sup>rd</sup> pcw – 75 years), in relation to their immunocompetent and neurogenetic roles. We identify developmental and postnatal waves of expansion and refinement, where the population undergoes marked changes in numbers, and we determine the contributions of proliferation, apoptosis and migration to this process. We validate our identified critical windows in further analyses of datasets from 251 bulk RNAseq samples and four single-cell RNAseq (scRNAseq) studies comprising 24,751 microglial cells spanning the embryonic and fetal ages (3-24 pcw). This study is pivotal for our understanding of human microglial biology, providing a granular view of the population dynamics across the life course and its intertwined nature with key neurodevelopmental processes. These findings serve as a solid basis for elucidating how microglia shape brain development in humans, key for understanding neurodevelopmental disorders.

## **RESULTS**

# Brain colonisation by microglia begins on the 4<sup>th</sup> postconceptional week (CS12)

The onset of embryonic circulation is concomitant with the development of the cardiovascular system, which in humans becomes functional from the late 3<sup>rd</sup>/early 4<sup>th</sup> pcw (somites: 4-12; CS10 onwards) (Tavian and Peault, 2005, O'Rahilly and Muller, 2010). At CS10, we identify early colonisation of embryonic organs such as the heart by cells committed to the myeloid lineage (PU.1<sup>+</sup>; Fig 2A), with expression of IBA1 not yet detected (Fig 2A). By CS12 (the end of the 4<sup>th</sup> pcw), organ colonisation by IBA1<sup>+</sup> cells (Fig 2B) is profuse. Proliferation is highest at CS16 (6<sup>th</sup> pcw) and lowest at CS21 (8<sup>th</sup> pcw) in the liver (Kruskal-Wallis p<0.05, multiple comparisons' adjusted p-values<0.01) (Fig 2C). Liver macrophage densities are not significantly different between pcw across the embryonic age (Kruskal-Wallis p>0.05, ns) (Fig 2C).

At CS10, no IBA1<sup>+</sup> or PU.1<sup>+</sup> myeloid cells are detected in the brain rudiment (Fig 2A). By CS12, the first wave of brain colonisation begins, with IBA1<sup>+</sup> macrophages seeding the forebrain, midbrain, and hindbrain (Fig 2B). Microglial proliferation increases sharply from CS12 to CS14 and remains relatively stable across the embryonic age with no significant differences in mean proliferation levels between pcw(s) (Kruskal-Wallis test, p>0.05, ns) (Fig 2C). The brain's proliferative index is much higher than the liver's (Mann-Whitney U test, p<0.05) but its IBA1 densities are significantly lower (Mann-Whitney U test, p<0.001) (Fig 2D). The first detectable expansion phase of the population is observed after a sharp increase in IBA1<sup>+</sup> cell density at

CS23 (9<sup>th</sup> pcw) compared to every pre-CS23 pcw (Kruskal-Wallis test, p<0.05, multiple comparisons adjusted post-hoc p-values<0.01) (Fig 2C).

In the developing brain, we found no significant differences between the cumulative distributions of microglia by sex for both density and proliferation (2-sample Kolmogorov-Smirnov test, p>0.05, ns) (Fig 2E, top). When we considered the mean proliferation and density by sex across the embryonic age, we also found no differences between males and females (Mann-Whitney U test, p>0.05) (Fig 2E, bottom). Early in development (5<sup>th</sup> pcw), migratory microglia (IBA1<sup>+</sup>) account for ~40% of the total population in the dorsal telencephalon, which, at this age, is bilaminar with a proliferative zone, the ventricular zone (VZ), and a plexiform mantle layer (ML) (Fig2B & Fig 2F, top). Based on a morphometric analysis, most of the migration in the VZ appears radial, indicating the colonisation of adjacent layers, whereas microglia in the ML are characterised by a tangential migratory phenotype, suggesting expansion within a layer (Fig 2F, bottom). Morphologically, microglia in the bilaminar telencephalon are amoeboid with or without a proliferative core, or migratory (tangential or radial) (Fig S1A).

Microglial densities and proliferation vary between regions: cell densities tend to be highest in the hindbrain at CS12 compared to the forebrain and midbrain (Fig 2G, fig S1B) through to CS21 and proliferation is significantly higher in the midbrain compared to the hindbrain and the forebrain (Friedman's test, p<0.05) (Fig S1B).

In sum, we can date the arrival of microglial progenitors to the brain at CS12 (4<sup>th</sup> pcw), with the population rapidly engaging in proliferative and migratory activities.

# The density of the microglial population fluctuates by waves of proliferation followed by cell death in the developing cortex

The future neocortex is formed from the dorsal telencephalon in the forebrain, which is where we focused all our subsequent analyses. Between CS12 (4<sup>th</sup> pcw) and CS21 (8<sup>th</sup> pcw), microglial proliferation is restricted to the ML (Fig 2B) and cells are seen entering the brain parenchyma from the VZ, the meningeal compartment and the ganglionic eminence (GE) (Fig 2H).

The last stage of embryonic life is CS23 (9<sup>th</sup> pcw) (O'Rahilly and Muller, 2010), equivalent to the late 8<sup>th</sup>/early 9<sup>th</sup> pcw, followed by fetal life. We observed key proliferation waves characterising the expansion of the microglial population during embryonic and early fetal lives:

This *first wave* is the most significant and coincides with the appearance of multiple transient layers in the telencephalon including the cortical plate (CP) and the presubplate (PSP) which becomes the subplate (SP) at the 12.5<sup>th</sup> pcw (Fig 3A-B, Fig S1C). This first wave is at the

transition between embryonic and fetal life (late 8<sup>th</sup>/early 9<sup>th</sup> pcw) (O'Rahilly and Muller, 2010, Kostovic et al., 2002), as evaluated with an excess test for bimodal distributions (B=100 replicas, modes: 2.04, 22.46; antimode: 16.35, p>0.05; (Ameijeiras-Alonso et al., 2019)). Mean proliferation levels are highest in the embryonic window (5-8 pcw) compared with early fetal windows (9-12 pcw, 13-16 pcw) (Kruskal-Wallis test p<0.01, multiple comparisons' adjusted posthoc p-values<0.01) (Fig 3C).

This increase in microglial proliferation (IBA1\*Ki67\*) is followed by a peak in density observed subsequently at 10-12 pcw (Fig 3B-C) in the frontal telencephalic wall. This first density wave in early fetal life is the most significant, evidenced by an excess test for bimodal distributions (B=100 replicas, modes: 85.77, 484.16; antimode: 426.84; p>0.05) (Fig 3B). Mean density levels are highest in the early fetal window (9-12 pcw) compared with 5-8 pcw and 13-16 pcw (Kruskal-Wallis test p<0.001, multiple comparison adjusted post hoc p-values <0.001) (Fig 3C, bottom panel).

From 12 pcw, the microglial density drops to baseline levels (Fig 3B) due to microglial apoptosis that we detect by cleaved Caspase 3 labelling in microglia between 12-16 pcw (Fig 3D). The mean percentage of apoptotic microglia before the density starts decreasing from 12 pcw was  $0.58 \pm 0.18$  % (7-11 pcw), increasing to  $2.94 \pm 0.83$  % after 12 pcw until 16 pcw (Mann-Whitney U test, p=0.007) (Fig 3D).

Between 9-10pcw we also detect a significant transient switch in the migratory phenotype of microglia, with most cells adopting a radial migratory pattern (Fig 3E), across all telencephalic layers (Fig S2), suggestive of a local colonisation process being coupled to cycles of expansion.

We complemented the IBA1 quantifications with an analysis of TMEM119 expression. This study may pose an opportunity to assess TMEM119, since there are conflicting reports in the literature about its validity as a *bona fide* microglial marker (Bennett et al., 2016, Vankriekelsvenne et al., 2022). TMEM119 cell density changes tracked the pattern followed by IBA1<sup>+</sup> cells between 9-16 pcw (Fig 3F). However, TMEM119 cell densities were significantly lower compared to IBA1 cells during this window (Wilcoxon test, p<0.01) (Fig 3F). TMEM119 densities correlated significantly with IBA1 densities (Spearman's r=0.84, p<0.005, Fig S3A) during development. The ratio of TMEM119/IBA1 labelled cells was ~10% between 10-28 pcw (Fig 3G) with a colocalisation degree of ~90% (Fig 3H, Fig S3B). Topographically, TMEM119<sup>+</sup> cells were strongly detected in the MZ and the VZ (Fig 3H). Sporadic expression of TMEM119 was detected in the lower portion of the CP but not in any other middle layers whilst IBA1 expression was consistent (Fig 3H). TMEM119<sup>+</sup> cells were not proliferative (Fig S3C) and co-expressed lysosomal marker CD68 particularly in the MZ (Fig S3D).

The second wave of proliferation was less significant (bimodal distribution excess test p>0.05) but will be described as similar patterns as the first wave were observed. The second

proliferation window coincides with the early expansion of the human subplate between 13-16 pcw (Kostovic, 2020) (Fig 3A-B). The increase in proliferation was followed by an increase in density which peaked at 20 pcw (Fig 3B). Thereafter, the density drops to baseline levels and closely matches the mean density values obtained in the adult (mean  $N_D = 84.63 \pm 4.41$  (mean cells/mm<sup>2</sup> $\pm$ SEM)). This drop in density can be explained by microglial apoptosis (cleaved Caspase 3<sup>+</sup>) between 18-24 pcw (Fig 3I). We also detect non-microglial apoptosis at various timepoints during development (Fig 3J).

The wave-like pattern followed by the microglial population during development is observed in both females and males (Fig 3B, 3K). No significant differences in microglial proliferation or density between the sexes were observed (Fig 3K) (Kolmogorov-Smirnov test, p>0.05 for distribution plots between males and females (Fig 3K, top), and Mann-Whitney U test for mean proliferation and density comparisons between males and females, p>0.05 (Fig 3K, bottom)). Microglial expansion is not uniform across transient zones of the developing cortex. As development progresses, we observed a pattern of "hot spots" of local proliferation preceding an increase in local density in subsequent timepoints, which is replicated across layers (Fig 4A-D). Every layer has a different timing: whereas densities peak earlier in development for the MZ, CP and SP (Fig 4A-C), they do so much later for the SVZ and the VZ (Fig 4A, 4D). Densities and proliferation are significant in the SP and IZ (Fig 4E) (Kruskal-Wallis test, adjusted p<0.01). Migration patterns vary within each layer (Fig S2) perhaps indicating movement of cells between adjacent layers.

During fetal life (9 pcw-term), microglial morphology is diverse: amoeboid, migratory (radial and tangential), clustered, ramified, bipolar and phagocytic/activated with pouches in the vicinity of the cell (Fig S1A and S4C-F). Some morphologies can be linked to function such as proliferative (IBA1\*Ki67\* cells), apoptotic (IBA1\*Casp3\*) and homeostatic (TMEM119\*) (Fig S1C,S2).

Altogether, post-colonisation at CS12 (4<sup>th</sup> pcw), the microglial population follows a wave-like pattern of significant increases in density preceded by increases in proliferation, later refined by cell death, with the ultimate consequence of densities stabilising at levels observed in the adult after every wave.

# Microglia undergo a wave-like pattern of transcriptional changes

We sought to validate our histological findings with an alternative approach based on the analysis of the transcriptional profile of microglia. Using bulk RNA-seq data from whole brain (Gerrelli et al., 2015, Lindsay et al., 2016), we examined the expression of genes characteristic of published adult and juvenile microglial signatures (Fig 5A (top panel), Data S1) across development (7-17 pcw). We considered a gene to be constitutively expressed when present

in >80% of the samples in every timepoint at a TPM value >2 (Fig 5A). We identified that 24% (212) of cortical genes from the adult signature were constitutively expressed in the telencephalon between 8-17 pcw (On genes; Fig 5A (bottom panel)). These genes are involved in the regulation of the innate immune and inflammatory responses as well as cytokine production (Fig 5A (right panel)). Heatmap representation of a set (75) of highly enriched microglial genes (Data S1) indicated a highly changeable signature with higher expression in the earlier timepoints (8 and 9 pcw) compared to later timepoints whereby only a few genes had high expression by 13-17 pcw (Fig 5B). The homeostatic marker P2RY12 had a stable expression throughout, whilst CX3CR1 increased gradually towards the 13-17 pcw temporal window (Fig 5C). Pro-inflammatory factors such as IRF5 and IFNGR1 had a stable expression throughout. The sensome gene CD37 had a 100-fold higher expression compared to other genes in our samples, declining with age. AIF1, encoding the ubiquitously expressed IBA1 protein, was expressed at low levels but consistently across the various ages (Fig 5C).

We identified a peak of differentially expressed (DE) genes at 9 pcw in the cortex (Fig 5D), matching the timing of the start of the first wave of expansion of microglial density (Fig 3). At 9pcw, we detected 81 DE genes: 27 upregulated DE genes were associated with chemokine and toll-like receptor signalling such as IRF5, SIGLECs (e.g. SIGLEC10) and MHC-II/costimulatory molecules such as HCG4B (Fig 5D & Data S1) and 54 downregulated DE genes were associated with cytokine-cytokine receptor signalling and interferon-gamma mediated signalling such as TGFBR1 (Fig 5D). Collectively, microglial DE genes are significantly associated with cellular components of immunological synapses and cytoplasmic, as well as, intracellular vesicles (Fig 5D).

We compared the expression of the microglial signature by region, testing samples from the cerebellum, the choroid plexus, the cortex and the midbrain (Fig 5E). We detected a substantial increase in the %DE genes in the midbrain and cerebellum at 7-8 pcw, prior to that seen in the cortex and choroid plexus between 9 and 10 pcw (Fig 5E). Although we did not perform deconvolution of cell-specific gene expression, this would suggest different regions may follow different microglial maturation timings. Thereafter, change in gene expression by region declined substantially with age (Fig 5E).

To further our analysis, we performed an integration of 4 available datasets from scRNA-seq of human brain myeloid cells (Bian et al., 2020, Kracht et al., 2020, Fan et al., 2020, Cao et al., 2020). We also considered including single cell data into our integrated single-cell dataset from (Li et al., 2018) as this study shows that deconvolution of tissue-level data against cell type—enriched markers for microglia follows an inverse sigmoidal curve. However, given the number of single cell microglial transcriptomes available (~5-10% of 1195 cells are likely to be microglial), it was unlikely that the pattern of our data would have changed significantly if we

had incorporated these data. Since each of the individual datasets from (Bian et al., 2020, Kracht et al., 2020, Fan et al., 2020, Cao et al., 2020) covered specific temporal windows, the integration allowed the analysis of an extended timeline (Table S1), similar to that analysed by immunohistochemistry (IHC) (Fig 3) and bulk RNAseq (Fig 5A-E). The initial integration identified the presence of cells expressing markers of erythrocytes in the original datasets (Fig. S5A), and we removed these and re-clustered to avoid any effects of contamination with nonmyeloid cells (Fig S5C). In the integrated dataset, we identified 8 clusters of microglia that express typical myeloid markers (see cluster markers in Data S2), among which are actively cycling and proliferating cells (cluster 5) (Fig 5F, Fig S5). The integration successfully represented all datasets, regardless of original number of cells (Fig S5D). The proliferation cluster also displayed a wave-like distribution across ages, first peaking at 9 pcw and then peaking again at 18pcw (Fig 5F, Fig S5), tracking the pattern we observed at the histological level. The alignment of cycling and proliferative microglia cells between the source data identified 40 conserved markers (Data S2). Gene ontology and protein-protein interaction enrichment analyses of these genes underscored their association with cell cycle processes (Fig 5 G-H), supporting the correct identification of these cells as proliferative microglia.

# Microglial proliferation is prominent in key neurodevelopmental structures

The fetal subplate (SP) is a major site for synaptogenesis, neuronal maturation and a waiting compartment for cortical afferents (Kostovic, 2020). Microglia are enriched in the PSP monolayer below the CP from the 10<sup>th</sup> pcw (Fig 3A, fig 4A). The SP is fully formed at 12.5 pcw by the gradual merging of the PSP and the deep loose portion of the CP in parallel with the development of the afferent fibre system (Kostovic, 2020). Microglia appear to track these key changes, appearing densely clustered in the SP with microglial proliferation highest in the SP and the IZ (Kruskal-Wallis test, adjusted p<0.01) (Fig 4E, Fig S4A-F).

By 15-20 pcw, we observed significant clustering of microglia in periventricular crossroads of projection and callosal pathways in the frontal lobe; these cells co-express MHCII and are non-proliferative (Fig S4C-E). By 20 pcw, microglia are evenly distributed throughout the expanding SP and only penetrate the upper portion of the CP by 25 pcw (Fig S4B). Dense clusters of microglia can be observed in the VZ from 22-28 pcw, colonising all the cortical layers by 28 pcw (Fig S4B). From 32 pcw, the 6-layered cortical Grundtypus can be observed with a resolving SP zone, and grey (GM) and white matters (WM) are clearly identifiable.

In sum, we found qualitative evidence of the intimate association of microglia with the key neurodevelopmental hallmarks that characterise brain formation and wiring.

The microglial population undergoes an expansion phase during infancy and childhood and is refined to adult levels by cell death

Postnatally, the microglial density increases from birth and, around 1-2 years of age, we observe a third wave. Though not statistically significant (Bimodal distribution excess test p>0.05), we thought it important to characterise given the challenge of obtaining samples during the crucial temporal window of early postnatal life, particularly infancy and childhood. Furthermore, the pattern observed resembles strikingly the developmental pattern. This third wave is characterised by a significant increase in proliferation during neonatal and infant life compared to adulthood and childhood (Kruskal-Wallis p<0.0001, adjusted p-values<0.001) (Fig 6A-B). This is followed by a 3-4-fold increase in densities in childhood in comparison with neonatal and adult densities (Kruskal-Wallis p<0.01, adjusted p-values<0.01) (Fig 6A-B). In childhood, proliferation decreases to levels observed in the adult, remaining constant through life (Fig 6A-B) (p>0.05 between adulthood and childhood). The mechanism through which microglial densities decrease after 1.5 years may be likened to the selection phase observed in rodents postnatally (Askew et al., 2017, Nikodemova et al., 2015) and we indeed detect microglial death (IBA1+Caspase3+) in the human cortex (Fig 6C). We found no significant differences between the cumulative distributions by sex for both density and proliferation (Kolmogorov-Smirnov test, p>0.05) (Fig 6D) or when comparing mean proliferation and densities by sex during postnatal life (0-75 years) (Mann-Whitney U test, p=0.09 for densities, p>0.2 for proliferation). Regionally, mean grey and white matter proliferative indices are similar in early postnatal life (neonate-child) (Fig 6E-G) and white matter densities are higher but not significant statistically (Fig 6F). White matter densities however are highest in the child compared with the infant, neonate and adult (Fig 6E-F) (Kruskal-Wallis p<0.01, adjusted p<0.05). The adult density and proliferation of microglia retain the previously described (Mittelbronn et al., 2001) higher density in the white matter (Fig 6G-H). From 18 years of age, throughout adult life and healthy ageing, the population has a slow turnover of 1.12 + 0.18 % and the density stabilises at 84.63 ± 4.42 cells/mm<sup>2</sup> (Fig 6H). The mean TMEM119 and IBA1 densities are similar during postnatal life (Fig 6I-J) (Wilcoxon test, p>0.05). Our TMEM119 findings were consistent with mouse studies showing limited/absent expression during the developmental period and an increased expression in postnatal life (Bennett et al., 2016). These analyses collectively identify that infancy and childhood are important temporal windows for microglial dynamics.

#### **DISCUSSION**

The past decade saw an exponential increase in experimental studies focusing on microglia, in part fuelled by the resolution of a long debate on the origins of these cells in mouse, by fate-mapping studies (Ginhoux et al., 2010). In humans, microglia enter the brain primordium prior to the onset of substantial neurogenesis and neuronal migration (Menassa and Gomez-Nicola,

2018). Recent studies indicate that microglia show marked heterogeneity during development, becoming immunocompetent from the 10<sup>th</sup> pcw (Kracht et al., 2020) with conserved ontogenic pathways between mouse and human (Bian et al., 2020). The population expands during embryonic life to yield the adult population, which maintains itself by cycles of self-renewal at a slow daily turnover rate (Askew et al., 2017, Réu et al., 2017, Nikodemova et al., 2015). Due to limited availability of healthy developmental human tissues, most of our knowledge of microglial development stems from rodent studies. Such studies have highlighted the roles that microglia play in shaping the neurodevelopmental landscape, including neuronal genesis, migration, dendritic development, axonal pruning, synaptogenesis, and wiring (Paolicelli et al., 2011, Squarzoni et al., 2014, Verney et al., 2010). However, until now we lacked a reference map for the development of microglia in humans, as an essential framework to contextualise basic studies and target human-relevant mechanisms.

Here, we have characterised the precise spatiotemporal dynamics of microglia in the frontal cortex across the human lifespan (3<sup>rd</sup> pcw – 75 years). We provide granularity and breadth, identifying critical temporal windows during development and postnatal life and defining processes fundamentally different from the known development of murine microglia, which will influence how we study the role of these cells in humans. This was achieved by the collection of post-mortem specimens from a multitude of tissue resources, enabling us to conduct a cross-sectional study with an extensive scope. We determine that microglia enter the telencephalon by the 4<sup>th</sup> pcw, mirroring, with some delay, the colonisation of peripheral organs by other tissue-resident macrophages. After colonisation, microglia undergo significant fluctuations in their cell density, characterised by newly identified wave-like patterns of proliferation followed by apoptosis. This is particularly evident at a key neurodevelopmental stage, the transition between embryonic and fetal life (9th pcw). This pattern is corroborated by bulk RNAseq and single-cell RNAseq analyses and coincides with the appearance of the cortical plate and transient zones. Throughout embryonic, fetal and postnatal development, the population transits through different cycles of expansion and apoptosis-driven refinement, stabilising during childhood and being maintained by self-renewal across the adult and older ages.

The elucidation of microglial dynamics during human cortical development offers new avenues for examining how these cells contribute to neurodevelopmental disorders. These cells participate in brain wiring pre- and postnatally (Menassa and Gomez-Nicola, 2018, Squarzoni et al., 2014, Paolicelli et al., 2011) and are involved in the pathophysiology of autism spectrum disorder (Tetreault et al., 2012, Carroll et al., 2021), schizophrenia (Sekar et al., 2016), and intellectual disability (Coutinho et al., 2017). With our identification of critical temporal windows of the population's expansion and refinement, we pave the way for uncharted territories in the field of neurodevelopmental disorders, which, with the current tissue resources in place, may

begin to closely characterise in space and time how the population alters the neurodevelopmental environment. We know that targeting microglial dynamics may have a therapeutic potential when these cells go awry, and this is likely to extend to the treatment of neurodevelopmental disorders (Olmos-Alonso et al., 2016).

One interesting, and somehow unexpected, finding of this study was the very limited, and in most cases absent, sex-dependent differences in the different variables we analysed related to microglial development. This is in contrast to previous rodent literature, which observed increased microglial density in males postnatally, as well as sex-dependent morphological changes lasting until juvenile and adult stages (Schwarz et al., 2012). Differences between developing microglia in male and female rodents have also been framed within the microglial developmental index (MDI), a compound index of transcriptional maturation. This program was found delayed in males relative to females, and sensitive to immune challenge (Hanamsagar et al., 2017). This perhaps underscores the urgent need to pivot to human or humanised models in order to understand the biology of microglia, in order to refine our knowledge of the contribution of this myeloid population to human brain function and dysfunction.

Our study was affected by a number of limitations, reflective of the scarcity of post-mortem brain samples from key ages. For example, we could not obtain tissues from childhood and adolescence, a period of protracted intracortical myelination in the frontal and temporal cortices in humans (Deoni et al., 2015). As we know, microglia follow myelination very closely (Menassa and Gomez-Nicola, 2018, Verney et al., 2010); the dynamics of the population have yet to be carefully defined during the critical window of intracortical myelination in humans. Early adolescence is a dynamic period and is important for the onset of some neuropsychiatric disorders (Penzes et al., 2011). Additionally, hormonal changes during puberty are likely to influence microglial dynamics and these could drive sex-specific effects. Another limitation relates to our definition of migration, which is inferred from morphometric analyses that may be less accurate in reflecting true microglial movement and did not allow us to distinguish between peripheral migration (into the brain) and within-brain migration. Microglia acquire a migratory phenotype subsequent to a proliferation cycle (Martín-Estebané et al., 2017) and our assessments here are of a possible migratory phenotype irrespective of contribution. We observed that within-brain migration may vary according to the topography of transient layers defined by the type of neurogenetic process. Overall, migration may contribute to the growth of the population at specific timepoints during development, thereafter, and once microglia are in the parenchyma and proliferating, they can acquire a migratory phenotype after each proliferative cycle to tile the anatomical local territory they are destined for.

Altogether, our findings identify key features of and relevant temporal windows for microglial population expansion and refinement across the human lifespan. This study provides a foundational map of the precise microglial spatiotemporal dynamics from early development through adulthood to healthy ageing. This resource will inform future research on how microglial cells participate in the neurodevelopmental landscape in humans and their relevance for neurodevelopmental disorders as they form part of the pathological signature of these conditions (Velmeshev et al., 2019, Coutinho et al., 2017).

#### **ACKNOWLEDGEMENTS**

The research was funded by the Leverhulme Trust (RPG-2016-311), the Medical Research Council (MRC) (MR/P024572/1) and the Alfonso Martin-Escudero Foundation (fellowship to M.M-E).

We would like to thank the joint MRC/Wellcome Trust Human Developmental Biology Resource (HDBR) (grant # MR/006237/1) (Gerrelli et al., 2015, Lindsay et al., 2016), the Zagreb Research Brain Collection (Hrabac et al., 2018), and BRAIN UK, a collaboration between representatives from the University of Southampton, Plymouth Hospitals NHS Trust, the University of Bristol, and a network of many NHS neuropathology centres across the United Kingdom. BRAINUK is funded by the MRC and Brain Tumour Research. In this study, the following NHS neuropathology centres that are part of BRAIN UK participated: The South-Central Oxford NHS Trust (the Thomas Willis Oxford Brain Bank), the South-Central Hampshire NHS Trust (Southampton Brain Bank) and the Cambridgeshire NHS Trust (Cambridge Brain Bank). We also thank the East Scotland NHS Trust (Edinburgh Brain Bank) and the North Somerset and South Bristol NHS Trust (Southwest Dementia Brain Bank) for providing tissues for this study. We would like to thank the Research Cooperability Program of the Croatian Science Foundation funded by the European Union from the European Social Fund under the Operational Programme Efficient Human Resources 2014-2020 PSZ-2019-02-4710 (ZK). Many thanks to the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project entitled Experimental and clinical research of hypoxicischemic damage in perinatal and adult brain; GA KK01.1.1.01.0007 funded by the European Union through the European regional development fund). We thank the Institutional Excellence in Higher Education Grant (FIKP) and Thematic Excellence Programme (National Research, Development and Innovation Office, Hungary), which supported the work of TT and IA. We would like to thank Steven Lisgo, Janet Kerwin, Tabitha Bloom, Carolyn Sloan, Chris-Anne McKenzie, Laura Palmer, Oliver Green, Poonam Singh, Danica Budinscak, Ana Bosak, Georgina Dawes, Jenny Dewing, David Chatelet, Olaf Ansorge, Thomas Jacques, Janja Kopić and Douglas Crockett for all their technical support in this project. We acknowledge the IRIDIS High Performance Computing Facility and associated support services at the University of Southampton towards the completion of this work.

#### **AUTHOR CONTRIBUTIONS**

DAM and DG-N designed the study. DG-N secured the funding and supervised the project. DAM contacted the relevant brain banks, organised the collection, performed all histological experiments, scanned the slides, and analysed the data. MM-E performed the migration analysis. TT and IA constructed the heatmaps and provided expertise about case selection. ZK and IK provided neuroanatomical expertise and neurogenetic analysis of microglial findings. MC performed the bulk-RNA-seq analysis. TAOM performed the scRNAseq analysis. JN assisted in the assessment of the neuropathology for case selection. LB-C and BT assisted with cell count analysis. DAM and DG-N wrote the manuscript. All authors contributed to drafting the manuscript.

#### **DECLARATION OF INTERESTS**

The authors declare no conflict of interest.

#### FIGURE LEGENDS

# Figure 1. Overview of the study.

(A) Post-mortem collection of human tissues across the lifespan with 52 prenatal and 45 postnatal cases which adds up to n = 97. The overall number of cases collected, sampled, and analysed was in excess of 130 (see methods section and tables S2). Temporal windows mapped onto key human neurodevelopmental milestones across the lifespan were defined consistent with existing classifications (Carroll et al., 2021, Silbereis et al., 2016, Kostovic et al., 2002): the embryonic period (3-8 pcw), the early fetal period (9-15 pcw), the mid-late fetal period (16-25 pcw), the preterm period (26-35 pcw), the term period (36 pcw-birth), the neonatal period (0-1 month), the infancy period (1-12 months), childhood (1-3 years) and adulthood (>18 years). Gene expression datasets: bulk RNAseq of 251 samples from the Wellcome MRC/HDBR resource in 4 anatomical regions between 7-17 postconceptional weeks and an integrated dataset of 24751 microglial cells from 4 single-cell RNAseg studies (Cao et al., 2020, Kracht et al., 2020, Bian et al., 2020, Fan et al., 2020) between 3-24 postconceptional weeks. F: Female; M: Male; MRC/HDBR: Medical Research Council/Human Developmental Biology Resource; †Not known; \*Brain banks that are part of the BRAINUK network. Embryonic brain drawings were based on our own samples, and other model brains were redrawn and coloured based on illustrations from (Haymaker and Adams, 1982).

# Figure 2. Early colonisation of the human embryo.

(A) Representative sagittal cross-section through a CS10 (late 3<sup>rd</sup> pcw) human embryo. Immunolabeling was done on consecutive 8 um sections identifying the presence of PU.1 cells in organs apart from the brain and the absence of IBA1+ cells overall. Scale bars: 500 µm (left); 40 µm (right). (B) Representative sagittal sections through whole human embryos from CS12, the age of appearance of IBA1<sup>+</sup> cells across the entire embryo, through to CS21. Insets show the location of proliferating IBA1<sup>+</sup> cells in both the liver and the dorsal telencephalon. Scale bars: 1 mm (top); 100 µm (bottom). (C) IBA1 proliferative dynamics and cell densities in the developing brain (n=14) and the liver (n=11). Black arrows represent the two most relevant timepoints for microglial densities: CS12 (4<sup>th</sup> pcw) for the first colonisation of the brain rudiment and CS23 (9<sup>th</sup> pcw), the transition from embryonic to early fetal life. (D) Mean IBA1 proliferation in the liver (n=11) and the developing brain (n=11) across the embryonic period. All data are shown as mean ± SEM. (E) Cumulative frequency distribution plots of densities and proliferative indices by sex in the developing brain (7F:7M) (top panel); mean differences between sexes in microglial densities and proliferative indices across the embryonic age in the developing brain (7F:7M) (bottom panel, data are shown as mean ± SEM). (F) Representative migratory profiles of IBA1<sup>+</sup> cells in the bilaminar telencephalon at 5 pcw (n=2).

Data are shown as mean  $\pm$  SEM). (G) IBA1<sup>+</sup> cell distributions in the CS12 embryo showing very few cells in the forebrain and a much higher density of cells in the hindbrain and midbrain. Scale bar: 500 µm. (H) Entry routes of IBA1<sup>+</sup> cells into the brain rudiment in the forebrain and the hindbrain. Scale bar: 100 µm. *C*: cardiac muscle; *CP*: cortical plate; *GE*: ganglionic eminence; *H*: hindbrain; *L*: liver; *M*: meninges; *MB*: midbrain; *Me*: mesenchyme; *ML*: mantle layer; *SC*: spinal cord; *T*: telencephalon; *VZ*: ventricular zone. For all panels, asterisks represent adjusted p-value significance as follows: \*p<0.05, \*\* p<0.001, \*\*\*, p<0.0001,ns p>0.05.

# Figure 3. Developmental dynamics of microglia in the cortex.

(A) Representative laminar structure of the developing cortex with its transient zones observed from CS23 (9<sup>th</sup> pcw) in humans and representative cortical columns from 10-12 pcw showing 1) the development of the pre-subplate to the subplate at 12.5 pcw and the alignment of microglial cells at the CP-PSP/SP boundary and 2) the distribution of microglial cells across transient zones. Scale bar: 2mm (left); 100 µm (right). (B) Corrected microglial densities (against fold change in frontal telencephalic wall thickness with age) and proliferative dynamics in the telencephalon during development (CS10 (late 3<sup>rd</sup>/early 4<sup>th</sup> pcw) until term (38 pcw) (n =50). \*n/k: not known. Embryonic and early fetal temporal windows are most significant for proliferation against other temporal windows whilst the early fetal window is the most significant against other temporal windows. (C) Equally-spaced temporal windows for proliferation levels (top) and densities (bottom) around the most significant first wave. Data are represented as mean ± SEM. (D) Mean apoptotic index around the first peak of densities (n=15, 8 cases between 7-11 pcw, 7 cases between 12-16 pcw) (top panel). Data are represented as mean ± SEM. ). Representative microglial cell death photomicrographs observed in wave 1 following the decrease in densities (bottom panel, black arrows in (B). Scale bar: 20 µm. (E) Migratory profile of microglia and type of migration in representative cases from the telencephalon (n=12). (F) Representative profile (top panel) of TMEM119<sup>+</sup> and IBA1<sup>+</sup> cell densities around the first significant density wave (10-16 pcw) (n=6). Mean TMEM119<sup>+</sup> and IBA1<sup>+</sup> cell densities across the prenatal period (10-28 pcw, n=10) (bottom panel). Data are shown as mean ± SEM. (G) Ratio of labelled TMEM119\*/IBA1\* cells during the prenatal period (10-28 pcw, n=10). Data are presented as mean ± SEM. (H) Representative confocal images of TMEM119<sup>+</sup> cells in the MZ and the VZ of a 13 pcw case (left) and double labelling of TMEM119/IBA1 in brightfield in a neocortical column at 13 pcw observed in the MZ (right). Scale bar (left): 50 µm, scale bar (right): 100 µm. (I) Wave 2 microglial cell death at 18 and 23 pcw. Scale bar: 20 µm. (J) Non-microglial death observed in the GE and in cortical transient zones at CS23 (9<sup>th</sup> pcw) (top, scale bar: 100 µm) and at 24 pcw (bottom, scale bar: 50 µm). (K) Proliferative dynamics and densities by sex across human development shown as relative cumulative frequency distribution plots (top panel) and mean values between the sexes (27M:23F) (bottom panel). Data are shown as mean  $\pm$  SEM). R: right; L: left; CP: cortical plate; GE: ganglionic eminence; IZ: intermediate zone; M: meninges; MZ: marginal zone; PSP: pre-subplate; SP: subplate; SVZ: subventricular zone; VZ: ventricular zone. For all panels, asterisks represent adjusted p-value significance as follows: p < 0.05, p < 0.001, p < 0.001, p > 0.05.

# Figure 4. Spatiotemporal microglial dynamics within the developing cortex.

(A) Representative heatmaps showing microglial dynamics throughout development in the human cortex. Heatmaps were constructed based on the density of immunoreactive cells. Density of all IBA1 immunoreactive cells are represented by blue-red spectral heatmaps (left column of each stage) while IBA1<sup>+</sup>/Ki67<sup>+</sup> double-positive cells are represented by purple-yellow spectral heatmaps (right column of each stage). Approximate densities are shown on the colour bar with minimal density being blue/purple, maximum density being red/yellow. All cortical columns are 450 μm wide. (B) Proliferation and densities of microglia in the marginal zone (n=35), cortical plate (n=31); (C) the subplate (n=31) and the intermediate zone (n=31); (D) the subventricular (n=31) and the ventricular zones (n=35). (E) Proliferation and densities in the subplate, the intermediate zone and remaining cortical layers. Data are shown as mean ± SEM. *CP:* cortical plate; *GM;* grey matter; *IZ*: intermediate zone; *MZ*: marginal zone; *PSP*: pre-subplate; *SP*: subplate; *SVZ:* subventricular zone; *VZ:* ventricular zone: *WM*: white matter. For all panels, asterisks represent adjusted p-value significance as follows: \*p<0.05, \*\*\* p<0.001, \*\*\*\*, p<0.0001,ns p>0.05.

# Figure 5. Microglial gene signature during development.

(A) 906 genes chosen from two published microglial-specific cortical adult and juvenile gene lists from (Gosselin et al., 2017, Galatro et al., 2017). Bar plot shows the number of constitutively expressed microglial genes ('On'), unexpressed genes ('Off') and those with sporadic expression in the developing cortex ('Other') with gene ontology analysis of constitutively expressed genes only. (B) Heatmap of highly enriched microglial genes during development (n = 75). (C) Transcript reads per million expression levels of a selection of homeostatic and immune modulatory microglial markers during development. (D) Volcano plot of upregulated and downregulated microglial genes at the peak of differential gene expression between 9 and 10 pcw with gene ontology analysis significant for cellular component. (E) Regional differential expression between timepoints of the cortical adult microglial genes. (F) Actively cycling and proliferating microglia in the scRNAseq dataset were identified across the gestational age. Only ages with a minimum of 50 cells were selected (7–24 pcw). Cycling and

proliferating cell signatures display a bimodal pattern of proliferation consistent with histological findings. (G) Metascape analysis of conserved cycling and proliferating microglia markers. (H) Gene ontology and protein-protein interaction enrichment analysis marking key mitotic cell cycle processes. Protein-protein interaction enrichment identifies mitotic spindle checkpoint and amplification of signals from the kinetochores (in red), as well as mitotic chromosome condensation and condensing I complex (in blue). DE: differentially expressed genes.

# Figure 6. Postnatal dynamics of microglia in the cortex.

(A) Microglial densities and proliferative dynamics in early postnatal life (n =24; 14M:10F) and adulthood (n=21; 14M:7F) and a representative cross-section of frontal cortex with anatomical histochemistry and photomicrographs of homeostatic and proliferating microglial morphologies in grey and white matters. Neonatal and infant proliferation is most significant against other postnatal windows whilst microglial densities are most significant in the child against other temporal windows. Scale bar: 2 mm (left); 40 µm (right). (B) Mean proliferation and mean densities in the neonate, the infant, child and adult. Data are shown as mean + SEM. (C) Microglial cell death in grey and white matter at 2 years (black arrow in (A)). Scale bar: 15 µm. (D) Cumulative relative frequency distribution plots of microglial densities and proliferation by sex (top panel) and mean proliferation and densities by sex (28M:17F) (bottom panel, data are shown as mean ± SEM). (E) Representative photomicrographs of cell densities in grey and white matters from birth to 2 years. Scale bar: 500 µm. (F) Regional differences of microglial densities and proliferation in grey (left) and white matters (right) between the neonate, infant, child and adult (n=45). Data are shown as mean ± SEM. (G) Proliferation rates and densities in early postnatal life in grey and white matters (n=24). Data are shown as mean ± SEM. (H) Regional differences in the adult in grey and white matter in proliferation (top) and density (bottom). Data are shown as mean ± SEM. (I) Mean TMEM119 and IBA1 cell densities postnatally (n=5) (left) and ratio of TMEM119/IBA1 between early life (3-6 months, n=2) and adult life (40-70 years, n=3). Data are represented as mean ± SEM. (J) Representative photomicrograph of TMEM119/IBA1 labelling showing colocalisation of both markers (black arrows). Scale bar: 25 µm. CC: cingulate cortex; GM: grey matter; WM: white matter. For all panels, asterisks represent adjusted p-value significance as follows: \*p<0.05, \*\* p<0.001, \*\*\*, p<0.0001,ns p>0.05.

#### **STAR METHODS**

## **RESOURCE AVAILABILITY**

#### **Lead Contact**

 Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Diego Gomez-Nicola (d.gomeznicola@soton.ac.uk).

# **Materials Availability**

This study did not generate new unique reagents.

# **Data and Code Availability**

- The integrated human single-cell RNA-seq dataset, and the developmental layer isolation macro are publicly available in Synapse (ID: syn33055573).
- Code is available in the Supplemental Items.
- Raw data is available upon request to the Lead Contact.

#### **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

#### **Human Tissues**

Human developmental tissues were obtained through the joint Medical Research Council (MRC)/Wellcome Trust Human Developmental Biology Resource (HDBR) (Gerrelli et al., 2015), the Zagreb Research Brain Collection (Hrabac et al., 2018) and BRAINUK neuropathology centres (Fig 1; table S2 for demographics of cases and acknowledgements for participating BRAINUK centres). Tissues were collected with appropriate maternal consent and approval for use in research. Ethical approval was obtained from the relevant ethics committees (Newcastle and North Tyneside NHS Health Authority Research Ethics Committee, Fulham NHS Health Authority Research Ethics Committee, South-Central Oxford C NHS Health Authority Research Ethics Committee and the South-Central Hampshire B NHS Health Authority Ethics Committee). Embryonic ages were estimated according to the Carnegie classification (CS) provided by the HDBR, CS23 being the last Carnegie stage equivalent to the 9<sup>th</sup> pcw. Gestational age corresponds to the time elapsed between the first day of the last menstrual period and the day of delivery (Engle et al., 2004). We used here postconceptional age consistent with HDBR guidelines which is estimated at 2 weeks earlier than gestational age (Table S2). For fetal developmental stages (age>9 pcw until term), cases were aged by a neuropathologist according to clinical notes. When possible, developmental

cases were sex-matched by timepoint. 63 developmental cases were initially sampled but only 52 developmental cases were included in the final study (n = 15 embryonic tissues; n = 37 fetal tissues; Fig 1 and table S2) between the late 3<sup>rd</sup> pcw (CS10) and 38 pcw (term). We excluded cases due to poor immunoreactivity (poor antigenicity) or evidence of hypoxic injury identified in the clinical notes (Fig S6A; table S2). Where possible, maternal data were provided (Table S10). Exclusion criteria, assessed against individual medical histories, included brain injury due to hypoxia-ischaemia or trauma, infection, or genetic mutations affecting brain structures. 71 postnatal cases were collected between 0 and 75 years of age with 45 of these cases in the final study. Early postnatal brain tissues (n = 24) aged between 0-2 years were obtained through BRAINUK. Adult brain tissues (n = 21) aged between 18-75 years were obtained with informed written consent and material approved for use for research purposes through the Zagreb Brain Collection, Edinburgh Brain Bank, the Cambridge Brain Bank and the Southwest Dementia Brain Bank. Ethical approvals were from the East Scotland NHS Research Ethics Service, the Cambridgeshire NHS Health Authority Research Ethics Committee and the North Somerset and South Bristol NHS Health Authority Research Ethics Committee, respectively. It was not possible to get sex-matching in postnatal cases (n = 45) and additional exclusion criteria included any neurological co-morbidity or a diagnosis of a connectivity disorder (e.g., autism spectrum disorder) (Table S4). We could not obtain samples from children aged between 3 and 17 years as these were scarce and, when present, the absence of consent prohibited the usage of these tissues for research.

All tissues were received as paraffin-embedded slices previously fixed in formalin phosphate buffer saline and sometimes with an added secondary fixative, methacarn (HDBR samples). Mid-sagittal embryonic sections of 8  $\mu$ m thickness were obtained through the whole embryo (up to CS21) allowing the visualisation of the brain rudiment and organs such as the heart, liver and spleen. All other sections, from CS23 until the late postnatal ages were processed coronally through the frontal axis of the brain at a thickness of 8  $\mu$ m.

## **Anatomy and Neuropathology**

Embryonic samples along the midsagittal axis included the telencephalic wall with its dorsal and ventral components. The frontal cortex (dorsolateral prefrontal, anterior cingulate) develops from the dorsal telencephalon (Bayer and Altman, 2008, Bayer and Altman, 2006). After CS21, the medial GE in the ventral telencephalon becomes more prominent. From CS23 onwards, developmental sections were all along the coronal axis of the frontal lobe with a prominent medial GE, an expanding telencephalic wall featuring transitional zones: the MZ, CP, PSP, SP, IZ, SVZ, VZ; Fig S1C). By 32 pcw, frontal cortex grey and the underlying white matters are developed, transitional zones have largely resolved, and brain structures begin to resemble those from adulthood. All sections were histochemically labelled with haematoxylin

and eosin according to standard methods, assessed by a neuropathologist for any signs of tissue pathology prior to analysis such as local or generalised hypoxia, haemorrhage, gliosis or neuronal death. Developmental tissue sections were histochemically labelled with filtered cresyl violet for the Nissl substance to visualise transitional zones for anatomical delineation as specified elsewhere (Duque et al., 2016, Kostovic et al., 2002). The SP was visualised by histochemical labelling of the extracellular matrix using the Periodic Acid Schiff Reagent-Alcian Blue method as specified elsewhere (Kostovic, 2020, Kostovic et al., 2002). White matter was visualised using the Gallyas silver labelling method by means of physical development (Gallyas, 1979).

#### **METHOD DETAILS**

# **Immunohistochemistry**

For immunostaining, sections were placed in an oven at 60°C for 45 min, dewaxed in 100% xylene solution, rehydrated in decreasing graded absolute ethanol (in distilled water) solutions and washed in water and 0.1% TWEEN 20-phosphate buffer saline (PBS-T) solution. Heatmediated antigen retrieval in 10 mM citrate buffer (pH=6.2) was subsequently performed on the sections in a microwave for 25 min. For early timepoints (CS10-CS13), 30 min antigen retrieval was performed using 0.5% sodium borohydride (213462, Sigma-Aldrich, UK). Then, sections were washed and/or cooled in cold tap water. Endogenous peroxidase and phosphatase activity in the tissues was quenched with a dual enzyme block from Dako (S2003, Agilent, UK). Sections were washed in 0.1% PBS-T and blocked with the relevant serum (goat, horse or rabbit) and 5% bovine serum albumin (BSA) in 0.2% PBS-T for one hour. Microglia were probed with a 24h incubation at 4°C with either a rabbit anti-human IBA1 antibody diluted in blocking solution (1:200, 019-19741, Wako chemicals, USA) or a goat antihuman IBA1 antibody (1:200, ab5076, Abcam, UK) or a mouse anti-human IBA1 antibody (1:200, ab283319, Abcam, UK). We used additional microglial markers including mouse anti-MHC-II/HLA-DP/DQ/DR (1:250, M077501-2, Agilent, UK), rabbit anti-PU.1 (1:200, 2258S, Cell Signalling, UK), biotinylated RCA1 (1:1000, B10855, Vector Labs, UK), rabbit TMEM119 (1:500, ab185333, Abcam, UK). We also used mouse an anti-human CD68 as a lysosomal marker (1:400, GA609, Dako, Agilent, UK) and a mouse anti-human SOX2 antibody (1:200, sc365823, Santa Cruz Biotechnology, USA) as a neuronal precursor cell marker. Mouse anti-Ki67 (1:400, M724029-2, Agilent, UK) was used to label proliferative cells and rabbit anticleaved-Caspase3 (1:40, 9664S, Cell Signalling, UK) was used to label apoptotic cells. Following incubation with the primary antibody, sections were washed with 0.1% PBS-T and incubated with the appropriate secondary antibodies. Secondary antibody double labelling was through an ImmPress Duet double staining anti-mouse HRP (brown)/anti-rabbit AP (magenta) kit (MP7724, Vector Laboratories, UK) according to the manufacturer's instructions;

horse anti-rabbit HRP using DAB chromogen with Nickel (SK100, Vector Laboratories, UK); horse anti-rabbit AP (blue) using a BCIP/NBT substrate kit (SK5400, Vector Laboratories, UK); rabbit anti-mouse secondary using the ImmPACT DAB-EqV HRP (brown) substrate kit (SK4103, Vector Laboratories, UK); signal amplification after species-specific secondary biotinylated antibody incubation of two hours was done using an avidin/biotin-based peroxidase system (PK6100, ABC Vectastain Elite kit, Vector Laboratories, UK). Chromogen development was sequential with double labelling. For triple labelling in brightfield, an additional DAB chromogen development was used, sections were re-quenched, re-blocked and probed with the relevant primary and secondary antibodies (bound to HRP) then developed with DAB + Nickel (SK4100, Vector Laboratories, UK). Chromogen development reactions were halted with distilled water, sections were washed with 0.1%PBS-T for 15 min then counterstained with methyl green (H3042, Vector Laboratories, UK) for 10 min or haematoxylin QS (H3404-100, Vector Laboratories, UK) for 30 seconds diluted 1:3 in distilled water. Sections were subsequently washed in distilled water for 5 min, then dehydrated in increasing gradients of absolute ethanol, cleared in xylene for 15 min, coverslipped with permanent mounting medium (DPX), dried for 24 hours then cleaned for scanning.

# **Immunofluorescence**

immunofluorescence, we followed the same protocol brightfield as our immunohistochemistry except for the following steps: no blocking needed against endogenous peroxidases and phosphatases. Secondary incubation against primary targets was done with the relevant secondary antibodies conjuguated to fluorophores (Goat-anti rabbit Alexafluor 488, 1:500 (Invitrogen, UK) and goat anti-mouse Alexafluor 568, 1:500 (Invitrogen, UK)) for 2 hours at room temperature. Slides were subsequently washed with PBS-T(0.1%) and incubated to guench autofluorescence with Trueblack lipofuscin autofluorescence guencher (23007, Biotium, USA) at 1:100 in 70% ethanol for 1 minute. Slides were washed with PBS-T(0.1%) and incubated for 5 min in 1:50000 DAPI in PBS then washed and coverslipped in Vectashield antifade mounting medium (H1000-10, Vector Laboratories, UK) in preparation for confocal imaging.

# **Confocal imaging**

Tissues labelled with fluorophores were scanned using an Olympus FV3000 confocal microscope (Olympus, Europe) with a 20x objective (UPlanSApo, NA 0.75, Olympus). Z-stacks were taken every 5 um for a total of 10-20 optical sections then Z-projected in imaFV31S-SW Fluoview software to reveal morphology. Pixel resolution was 0.45 um x 0.45

um in (x, y). All images were imaged in three channels using the 488, 568 and 350 nm laser lines.

# Image analysis

Slides were digitised using a VS110 high-throughput virtual microscopy system (Olympus, Japan), an Aperio Scanscope AT Turbo system (Leica Biosystems, UK) or a 2.0 RS Nanozoomer high-throughput system (Hamamatsu Photonics, Japan). Pixel resolution was 172.35 nm/pixel in x, y and z. From the scans, regions of interest were extracted, and brain/layer thicknesses were measured in the relevant slide viewers (VS110-Desktop (v4), Aperio ImageScope (v12.4.3), NDP.view2). Images were processed using Fiji (Schindelin et al., 2012). The analysis pipeline included re-scaling the images, deconvolving the signal and calculating a cell density (in cells/mm<sup>2</sup>) based on absolute counts until CS23. Beyond that age, between 500-1000 cells/case were sampled. While stereological methods could not be used due to the limited tissue available as well as the thickness of sections obtained, this approach was deemed sufficient to provide a representative value of brain IBA1 densities consistent with unbiased sampling methods (Herculano-Houzel et al., 2015). The proliferative index -I- of microglia was calculated as follows: I = (number of double positive (IBA1/Ki67) cells/total number of IBA1 cells) x 100 (see also (Askew et al., 2017)). Double positives were confirmed by deconvolution (Fig S6B). Prenatally, we calculated fold change values between subsequent ages based on overall cortical wall or individual layer thickness measurements to account for brain/layer growth rates during development. Postnatally, we collected brain weight data (when available) from the clinical notes of analysed cases and calculated the fold change increase in brain weight between subsequent ages and applied this correction to our density data. Proliferation index was independent of the changes in brain growth rates. Individual layers were manually traced in Fiji using a macro (Synapse ID: syn33055573) and a cell density was calculated as  $N_D$  = (Number of cells/area (mm<sup>2</sup>)).

# Analysis of TMEM119/IBA1 cells

In a subset of cases (n = 15, 10 prenatal and 5 postnatal) and along the frontal neocortical wall, we calculated the density of TMEM119<sup>+</sup> and IBA1<sup>+</sup> cells and the ratio between TMEM119<sup>+</sup>/IBA1<sup>+</sup> densities to determine the percentage labelled by each marker. We also performed colocalisation analyses using two methods in brightfield: the colocalisation algorithm in Aperio imagescope (Leica Biosystems, UK) and using the deconvolution plugin in Fiji software (Fig S3B).

# Calculation of the apoptotic index

We quantified IBA1<sup>+</sup> cells positive for active cleaved Caspase 3 as a marker of cell death. Apoptotic cells undergo nuclear and cytoplasmic degradation that can be visible under haematoxylin and eosin histochemistry too. Cells show eosinophilic changes in the cytoplasm early in the process with a pyknotic nucleus. Further on, the nuclear envelope disintegrates, and the eosinophilic cytoplasm shrinks before the cell undergoes karyorrhexis or the breakdown of nuclear material altogether (Sierra et al., 2013, Love et al., 2015). We calculated the apoptotic index for a selection of cases around the main peak of the most significant increase in microglial densities (n=15; 8 pre-peak between 7-11 pcw and 7 post-peak between 12-16 pcw). The index was calculated as a percentage of double positive cells for cleaved caspase 3 and IBA1 against the total number of IBA1<sup>+</sup> cells. Overall, if we approximated the total number of cells lost per day per square mm based on our mean density measurements after the peak, we could only account for a fraction of the lost cells per week (approximately 9 cells per square mm). Given the rapid tagging of a cell with active caspase 3 (~5 min) ((Sierra et al., 2013), which may be further compounded by sensitive antigenicity in formalin-fixed paraffin-embedded tissues, it is possible that the index is an underestimation.

## Migration analysis

The migratory phenotype of microglia (IBA1<sup>+</sup> cells) was inferred using morphometric analysis in Fiji (Schindelin et al., 2012). While dynamic processes such as migration cannot be easily assessed in static images, we used morphological determinants to determine the possible migratory status of microglia based on studies that have linked microglial phenotype to their migratory state in different stages of development (Harry, 2013, Sánchez-López et al., 2004, Martín-Estebané et al., 2017, Marín-Teva et al., 1999, Marín-Teva et al., 1998, Cuadros and Navascués, 1998, Rezaie and Male, 1999, Swinnen et al., 2013). Microglia in adult brain are not polarised since they are already differentiated into their final and ramified morphology (thin and long branches). However, during development, microglia are amoeboid and they show short but thick pseudopodia which they use to migrate along fibres of radial glia, white matter systems and blood vessels. These two morphologies are very different, and they can be found in different developmental stages. In quail, these have been described alongside the movement of microglia using pseudopodia, which is a similar phenotype to the one we observed in the human samples: cells with thick processes that are very polarised in parallel to fibre layers or radial glia along the layers. The circularity parameter was used to select out the migratory phenotype in each layer: if circularity<0.3, a cell would be considered migratory and if circularity>0.3, it would be non-migratory (Fig S6C). We also assessed the type of migration (radial or tangential) by measuring the angle formed between the major axis of the cell and the corresponding layer plane (Fig S6C), considering an angle<45 degrees as tangential migration and an angle>45 degrees as radial migration. Developmental timepoints considered were selected based on the cell density profile whereby an increase could not be explained by proliferation alone. We studied migration between 5 and 26 pcw (n=2/timepoint).

# Histological heatmaps

For the visualization of cell densities as heatmaps, cortical columns per stage were manually annotated in Aperio ImageScope software (v12.4.3), LeicaBiosystems, IL, USA) (Fig S6D). At least 2 cases by timepoint were analysed and the most representative column was used for visualisation in the final spatiotemporal profile. IBA1 $^+$  and IBA1 $^+$ /Ki67 $^+$  double-positive cells were analysed separately. Coordinates of the annotated cells were exported into Quantum Geographic Information System QGIS (v2.18.3, Hannover, Germany), a spatial analysis software. The heatmap module in QGIS with metric projection EOV23700 was used. We used a sampling radius of 150 µm, with a maximum value of 4, which meant that on the red area of a computed heatmap in a  $(0,15)^{2*}\pi$  mm $^2$  area of a circle, at least 4 cells could be located. Subsequently, proportionally extrapolated values were used to estimate the density in cells/mm $^2$ . Heatmaps were exported and superimposed onto their respective immunohistochemically labelled spatial maps using Gimp 2.10.22 annotating the anatomical boundaries.

## **Bulk RNA-sequencing analysis**

We sourced published lists of genes from adult and adolescent human cortical microglia (Galatro et al., 2017, Gosselin et al., 2017). 906 microglia genes were identified (Data S1) and were mapped onto an available bulk-RNAseq dataset from the HDBR. We utilised 251 samples of tissues ranging in age from 7 to 17 pcw. Four anatomical regions were considered: telencephalon (n = 94), cerebellum (n = 79), choroid plexus (n = 28) and midbrain (n = 50). Full details of the source, collection, preparation and sequencing of human fetal RNA samples have been described previously (Gerrelli et al., 2015, Lindsay et al., 2016) (https://www.hdbr.org/expression/). Data were downloaded from SRA as FASTQ files. Quality control was carried out using Trimmomatic to remove poor quality bases, reads with too many poor-quality bases and short reads using the following settings: ILLUMINACLIP:/local/software/trimmomatic/0.32/adapters/TruSeg3-PE-2.fa:2:30:10 LEADING:5 TRAILING:5 SLIDINGWINDOW:4:15 MINLEN:72. After this, unpaired reads were excluded from further analysis. STAR v2.5.2b (Dobin et al., 2013) was used to map reads GRCh38 genome using settings --outFilterMismatchNmax 10 -outFilterMismatchNoverReadLmax 0.05 and the result outputted as .sam files, which were

sorted using Samtools (v1.1, (Li et al., 2009)). Read counts were calculated per gene using HTSeq count (in the HTSeq v0.6.1 package; (Anders et al., 2015)) and the GRCh38 general feature format file. Differential gene expression analysis was carried out using EdgeR (Robinson et al., 2010, Soneson and Robinson, 2018) in Trinity (v2.4.0) (Haas et al., 2013) on raw read counts. Heatmaps were generated using *analyze\_diff\_expr.pl* in Trinity (Haas et al., 2013) and the TMM-normalised counts. Gene Ontology (GO) terms over-represented in the list of DE genes were identified using the plug-in available at the Gene Ontology resource.

# Single-cell RNA-sequencing analysis

To validate our histological and bulk-RNAseq findings, we analysed 4 datasets from recently published developmental single-cell RNA-sequencing studies of human brain cells (Cao et al., 2020, Fan et al., 2020, Bian et al., 2020, Kracht et al., 2020) and generated an integrated dataset spanning 3 to 24 pcw (Bian et al., 2020, Kracht et al., 2020). We accessed the genecell count matrix and cell annotation matrix data and used Seurat (v3.2.2) for all analyses (Stuart et al., 2019). Guided by the original authors' annotations, we enriched for microglial cells by selecting for "Immune", "Mac 1", "Mac 2", "Mac 3", "Mac 4", and "Microglia"annotated clusters. We then utilized the 3 x Mean Absolute Deviation (MAD) for outlier cut-off across 4 parameters where available: nCount RNA, nFeature RNA, percent.mt, percent.rb (Kracht et al., 2020, Daniszewski et al., 2018, Waise et al., 2019). After quality control, the final integrated dataset used for our analyses contained 24,751 transcriptomes, 8,117 of which were nuclei. Standard Seurat SCTransform integration was performed, selecting 3,000 features for anchor identification and integration and regressing for nCount RNA, nFeature RNA, percent.mt, and/or percent.rb (Fig S5). We detected immediate-early gene expression suggestive of dissociation-induced artefacts. However, a discussion of these effects in human tissue was beyond the scope of the study and were not selected for regression. We also identified a cluster enriched for erythrocyte (ERY) markers (e.g. HBG2, HBB) (Fig S5). The single-nuclei dataset by (Cao et al. 2020) contributed most of the cells of this ERY cluster, suggesting that this cluster is a technical, method-specific artefact, albeit all datasets showed some degree of ERY (Fig S5). We considered regressing for such effects, however, doing so risks distorting transcriptional heterogeneity. To minimize these effects in our analysis, we removed the ERY cluster and re-clustered prior to our analysis of actively cycling and proliferating cells. 8 principal components were selected for dimensionality reduction and combined with a resolution of 0.5, to visualize transcriptional heterogeneity across human development spanning 3 to 24 pcw. Cell cycle phase was determined with 'CellCycleScoring' to identify actively proliferating cells. Only ages with more than 50 cells were selected for the proliferation wave signature. Data were visualized using DimPlot, FeaturePlot, VInPlot and DoHeatmap functions, and differential expression analysis was

performed with MAST (Finak et al., 2015). Alignment of actively cycling and proliferating cells between source data was done utilizing the 'FindConservedMarkers' function of the Seurat package and gene ontology and protein-protein interaction enrichment analyses was performed with *Metascape*.

#### **QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical analysis and visualisations were done in RStudio and GraphPad Prism. We have used non-parametric techniques in our analyses and therefore, made no assumptions about data distributions or homoscedasticity. All information about statistical details per experiment can be found in the figure captions and the results section. In brief here, non-parametric correlations using Spearman's tested associations between brain weight, layer thicknesses, age and densities with different markers. Sex differences were assessed using cumulative distribution plots with the 2-sample Kolmogorov-Smirnov test and means' differences were tested using the Mann-Witney U test. Friedman's test was used to test for differences between layers within matched data. Wilcoxon test was used to test differences between matched data (liver and brain from the same cases for example). We also fitted non-parametric regression lines to density and proliferation data using the following parameters: a Loess regression function with a medium number of 10 points followed by a smoothing spline function with 6-8 knots as smoothing factors, which were both recommended by Graphpad Prism. We tested centred polynomial models of up to the maximum recommended order (6<sup>th</sup> order) to model our data but these could explain at most 60% of the variance. Therefore, these were not suitable and we opted for presenting all datapoints instead and applying non-parametric functions that follow the data trend with no assumptions about a model that could fit all data. Increasing the order of polynomial models may have improved variance but would have resulted in overfitting. Furthermore, biological fluctuations that we report in the microglial population underlie the difficulty of finding one model that fits all data. To test multimodality of data distributions, we used a non-parametric bootstrap approach with B=100 replicas and (Ameijeiras-Alonso et al. 2019) excess test which if significant would accept the null-hypothesis that our data distribution for proliferation or density had a number of modes that was greater than 1. This test was run on the entire dataset (3 pcw - 75 years of age, n=95) and we have reported the modes and the antimodes. To test for significance between temporal windows for density and proliferation, we compared mean ranks in temporal windows around the fitted regression lines using a nonparametric Kruskal-Wallis test corrected for multiple comparisons using Graphpad's recommended tests (Dunn's, Benjamini-Krieger) and report throughout the adjusted p-values. Temporal windows were either equally-spaced and data were grouped accordingly. To place these temporal windows within relevant human milestones, we also grouped data according

to existing nomenclature as follows: embryonic (3-8 pcw), early fetal (9-15 pcw), mid-late fetal (16-25 pcw), preterm (26-35 pcw), term (36 pcw-birth), neonatal (0-1 month), infant (1 month-12 months), child (1 year-2 years, only in our study because we did not have samples between 2-12 years), and adult (>18 years) (Silbereis et al., 2016, Kostovic et al., 2002, Carroll et al., 2021). For postnatal stages, we used the Mann-Whitney U non-parametric test to report significant differences between means. For RNA-seq data (single cell and bulk), p-values, including those related to analysis of DE genes, were corrected for FDR in EdgeR using the Benjamini-Hochberg correction. Volcano plots and heatmaps were plotted in RStudio. Hierarchical clustering was carried out in Trinity (Haas et al., 2013). Histological heatmaps were plotted using QGIS spatial analysis software as elaborated upon in the relevant methods section.

Table S3. Maternal demographics, Related to figure 1, 2, 3, 4 & methods.

Data S1. RNAseq gene lists, Related to figure 1, 5 & methods.

Data S2. Gene lists used for scRNAseq analysis, Related to figure 5 & methods.

#### REFERENCES

- AMEIJEIRAS-ALONSO, J., CRUJEIRAS, R. M. & RODRÍGUEZ-CASAL, A. 2019. Mode testing, critical bandwidth and excess mass. *TEST*, 28, 900-919.
- ANDERS, S., PYL, P. T. & HUBER, W. 2015. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics*, 31, 166-9.
- ASKEW, K., LI, K., OLMOS-ALONSO, A., GARCIA-MORENO, F., LIANG, Y., RICHARDSON, P., TIPTON, T., CHAPMAN, M. A., RIECKEN, K., BECCARI, S., SIERRA, A., MOLNAR, Z., CRAGG, M. S., GARASCHUK, O., PERRY, V. H. & GOMEZ-NICOLA, D. 2017. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain. *Cell Rep.* 18, 391-405.
- BADIMON, A., STRASBURGER, H. J., AYATA, P., CHEN, X., NAIR, A., IKEGAMI, A., HWANG, P., CHAN, A. T., GRAVES, S. M., UWERU, J. O., LEDDEROSE, C., KUTLU, M. G., WHEELER, M. A., KAHAN, A., ISHIKAWA, M., WANG, Y. C., LOH, Y. E., JIANG, J. X., SURMEIER, D. J., ROBSON, S. C., JUNGER, W. G., SEBRA, R., CALIPARI, E. S., KENNY, P. J., EYO, U. B., COLONNA, M., QUINTANA, F. J., WAKE, H., GRADINARU, V. & SCHAEFER, A. 2020. Negative feedback control of neuronal activity by microglia. *Nature*, 586, 417-423.
- BAYER, S. A. & ALTMAN, J. 2006. The human brain during the late first trimester. *Atlas of human central nervous system development v 4.* Boca Raton: CRC Press,.
- BAYER, S. A. & ALTMAN, J. 2008. The human brain during the early first trimester. *Atlas of human central nervous system development*. Boca Raton, Fla.

London: CRC;

Taylor & Francis distributor ,.

- BENNETT, F. C., BENNETT, M. L., YAQOOB, F., MULINYAWE, S. B., GRANT, G. A., HAYDEN GEPHART, M., PLOWEY, E. D. & BARRES, B. A. 2018. A Combination of Ontogeny and CNS Environment Establishes Microglial Identity. *Neuron*, 98, 1170-1183 e8.
- BENNETT, M. L., BENNETT, F. C., LIDDELOW, S. A., AJAMI, B., ZAMANIAN, J. L., FERNHOFF, N. B., MULINYAWE, S. B., BOHLEN, C. J., ADIL, A., TUCKER, A., WEISSMAN, I. L., CHANG, E. F., LI, G., GRANT, G. A., HAYDEN GEPHART, M. G. & BARRES, B. A. 2016. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A*, 113, E1738-46.
- BIAN, Z., GONG, Y., HUANG, T., LEE, C. Z. W., BIAN, L., BAI, Z., SHI, H., ZENG, Y., LIU, C., HE, J., ZHOU, J., LI, X., LI, Z., NI, Y., MA, C., CUI, L., ZHANG, R., CHAN, J. K. Y., NG, L. G., LAN, Y., GINHOUX, F. & LIU, B. 2020. Deciphering human macrophage development at single-cell resolution. *Nature*, 582, 571-576.

- CAO, J., O'DAY, D. R., PLINER, H. A., KINGSLEY, P. D., DENG, M., DAZA, R. M., ZAGER, M. A., ALDINGER, K. A., BLECHER-GONEN, R., ZHANG, F., SPIELMANN, M., PALIS, J., DOHERTY, D., STEEMERS, F. J., GLASS, I. A., TRAPNELL, C. & SHENDURE, J. 2020. A human cell atlas of fetal gene expression. *Science*, 370.
- CARROLL, L., BRAEUTIGAM, S., DAWES, J. M., KRSNIK, Z., KOSTOVIC, I., COUTINHO, E., DEWING, J. M., HORTON, C. A., GOMEZ-NICOLA, D. & MENASSA, D. A. 2021. Autism Spectrum Disorders: Multiple Routes to, and Multiple Consequences of, Abnormal Synaptic Function and Connectivity. *Neuroscientist*, 27, 10-29.
- COUTINHO, E., MENASSA, D. A., JACOBSON, L., WEST, S. J., DOMINGOS, J., MOLONEY, T. C., LANG, B., HARRISON, P. J., BENNETT, D. L. H., BANNERMAN, D. & VINCENT, A. 2017. Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero. *Acta Neuropathol*, 134, 567-583.
- CUADROS, M. A. & NAVASCUÉS, J. 1998. The origin and differentiation of microglial cells during development. *Prog Neurobiol*, 56, 173-89.
- CUNNINGHAM, C. L., MARTINEZ-CERDENO, V. & NOCTOR, S. C. 2013. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. *J Neurosci*, 33, 4216-33.
- DANISZEWSKI, M., SENABOUTH, A., NGUYEN, Q. H., CROMBIE, D. E., LUKOWSKI, S. W., KULKARNI, T., SLUCH, V. M., JABBARI, J. S., CHAMLING, X., ZACK, D. J., PEBAY, A., POWELL, J. E. & HEWITT, A. W. 2018. Single cell RNA sequencing of stem cell-derived retinal ganglion cells. *Sci Data*, 5, 180013.
- DEONI, S. C., DEAN, D. C., 3RD, REMER, J., DIRKS, H. & O'MUIRCHEARTAIGH, J. 2015.

  Cortical maturation and myelination in healthy toddlers and young children.

  Neuroimage, 115, 147-61.
- DOBIN, A., DAVIS, C. A., SCHLESINGER, F., DRENKOW, J., ZALESKI, C., JHA, S., BATUT, P., CHAISSON, M. & GINGERAS, T. R. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, 29, 15-21.
- DUQUE, A., KRSNIK, Z., KOSTOVIC, I. & RAKIC, P. 2016. Secondary expansion of the transient subplate zone in the developing cerebrum of human and nonhuman primates. *Proc Natl Acad Sci U S A*, 113, 9892-7.
- ENGLE, W. A., AMERICAN ACADEMY OF PEDIATRICS COMMITTEE ON, F. &

  NEWBORN 2004. Age terminology during the perinatal period. *Pediatrics*, 114, 13624
- FAN, X., FU, Y., ZHOU, X., SUN, L., YANG, M., WANG, M., CHEN, R., WU, Q., YONG, J., DONG, J., WEN, L., QIAO, J., WANG, X. & TANG, F. 2020. Single-cell transcriptome

- analysis reveals cell lineage specification in temporal-spatial patterns in human cortical development. *Sci Adv*, 6, eaaz2978.
- FINAK, G., MCDAVID, A., YAJIMA, M., DENG, J., GERSUK, V., SHALEK, A. K., SLICHTER, C. K., MILLER, H. W., MCELRATH, M. J., PRLIC, M., LINSLEY, P. S. & GOTTARDO, R. 2015. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol.* 16, 278.
- GALATRO, T. F., HOLTMAN, I. R., LERARIO, A. M., VAINCHTEIN, I. D., BROUWER, N., SOLA, P. R., VERAS, M. M., PEREIRA, T. F., LEITE, R. E. P., MOLLER, T., WES, P. D., SOGAYAR, M. C., LAMAN, J. D., DEN DUNNEN, W., PASQUALUCCI, C. A., OBA-SHINJO, S. M., BODDEKE, E., MARIE, S. K. N. & EGGEN, B. J. L. 2017. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. *Nat Neurosci*, 20, 1162-1171.
- GALLYAS, F. 1979. Silver staining of myelin by means of physical development. *Neurol Res,* 1, 203-9.
- GERRELLI, D., LISGO, S., COPP, A. J. & LINDSAY, S. 2015. Enabling research with human embryonic and fetal tissue resources. *Development*, 142, 3073-6.
- GINHOUX, F., GRETER, M., LEBOEUF, M., NANDI, S., SEE, P., GOKHAN, S., MEHLER, M. F., CONWAY, S. J., NG, L. G., STANLEY, E. R., SAMOKHVALOV, I. M. & MERAD, M. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science*, 330, 841-5.
- GOMEZ-NICOLA, D. & PERRY, V. H. 2015. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. *Neuroscientist*, 21, 169-84.
- GOSSELIN, D., LINK, V. M., ROMANOSKI, C. E., FONSECA, G. J., EICHENFIELD, D. Z., SPANN, N. J., STENDER, J. D., CHUN, H. B., GARNER, H., GEISSMANN, F. & GLASS, C. K. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell*, 159, 1327-40.
- GOSSELIN, D., SKOLA, D., COUFAL, N. G., HOLTMAN, I. R., SCHLACHETZKI, J. C. M., SAJTI, E., JAEGER, B. N., O'CONNOR, C., FITZPATRICK, C., PASILLAS, M. P., PENA, M., ADAIR, A., GONDA, D. D., LEVY, M. L., RANSOHOFF, R. M., GAGE, F. H. & GLASS, C. K. 2017. An environment-dependent transcriptional network specifies human microglia identity. *Science*, 356.
- HAAS, B. J., PAPANICOLAOU, A., YASSOUR, M., GRABHERR, M., BLOOD, P. D., BOWDEN, J., COUGER, M. B., ECCLES, D., LI, B., LIEBER, M., MACMANES, M. D., OTT, M., ORVIS, J., POCHET, N., STROZZI, F., WEEKS, N., WESTERMAN, R., WILLIAM, T., DEWEY, C. N., HENSCHEL, R., LEDUC, R. D., FRIEDMAN, N. &

- REGEV, A. 2013. De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis. *Nat Protoc*, 8, 1494-512.
- HANAMSAGAR, R., ALTER, M. D., BLOCK, C. S., SULLIVAN, H., BOLTON, J. L. & BILBO, S. D. 2017. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. *Glia*, 65, 1504-1520.
- HARRY, G. J. 2013. Microglia during development and aging. *Pharmacol Ther*, 139, 313-26.
- HAYMAKER, W. & ADAMS, R. D. 1982. *Histology and histopathology of the nervous system,* Springfield, Ill., Thomas.
- HERCULANO-HOUZEL, S., VON BARTHELD, C. S., MILLER, D. J. & KAAS, J. H. 2015. How to count cells: the advantages and disadvantages of the isotropic fractionator compared with stereology. *Cell Tissue Res*, 360, 29-42.
- HRABAC, P., BOSAK, A., VUKSIC, M., JUDAS, M., KOSTOVIC, I. & KRSNIK, Z. 2018. The Zagreb Collection of human brains: entering the virtual world. *Croat Med J*, 59, 283-287.
- JANOSSY, G., BOFILL, M., POULTER, L. W., RAWLINGS, E., BURFORD, G. D., NAVARRETE, C., ZIEGLER, A. & KELEMEN, E. 1986. Separate ontogeny of two macrophage-like accessory cell populations in the human fetus. *J Immunol*, 136, 4354-61.
- KOSTOVIC, I. 2020. The enigmatic fetal subplate compartment forms an early tangential cortical nexus and provides the framework for construction of cortical connectivity. *Prog Neurobiol*, 194, 101883.
- KOSTOVIC, I., JUDAS, M., RADOS, M. & HRABAC, P. 2002. Laminar organization of the human fetal cerebrum revealed by histochemical markers and magnetic resonance imaging. *Cereb Cortex*, 12, 536-44.
- KRACHT, L., BORGGREWE, M., ESKANDAR, S., BROUWER, N., CHUVA DE SOUSA LOPES, S. M., LAMAN, J. D., SCHERJON, S. A., PRINS, J. R., KOOISTRA, S. M. & EGGEN, B. J. L. 2020. Human fetal microglia acquire homeostatic immune-sensing properties early in development. *Science*, 369, 530-537.
- LAVIN, Y., WINTER, D., BLECHER-GONEN, R., DAVID, E., KEREN-SHAUL, H., MERAD, M., JUNG, S. & AMIT, I. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell*, 159, 1312-26.
- LI, H., HANDSAKER, B., WYSOKER, A., FENNELL, T., RUAN, J., HOMER, N., MARTH, G., ABECASIS, G., DURBIN, R. & GENOME PROJECT DATA PROCESSING, S. 2009.

  The Sequence Alignment/Map format and SAMtools. *Bioinformatics*, 25, 2078-9.
- LI, M., SANTPERE, G., IMAMURA KAWASAWA, Y., EVGRAFOV, O. V., GULDEN, F. O., POCHAREDDY, S., SUNKIN, S. M., LI, Z., SHIN, Y., ZHU, Y., SOUSA, A. M. M., WERLING, D. M., KITCHEN, R. R., KANG, H. J., PLETIKOS, M., CHOI, J.,

- MUCHNIK, S., XU, X., WANG, D., LORENTE-GALDOS, B., LIU, S., GIUSTI-RODRÍGUEZ, P., WON, H., DE LEEUW, C. A., PARDIÑAS, A. F., HU, M., JIN, F., LI, Y., OWEN, M. J., O'DONOVAN, M. C., WALTERS, J. T. R., POSTHUMA, D., REIMERS, M. A., LEVITT, P., WEINBERGER, D. R., HYDE, T. M., KLEINMAN, J. E., GESCHWIND, D. H., HAWRYLYCZ, M. J., STATE, M. W., SANDERS, S. J., SULLIVAN, P. F., GERSTEIN, M. B., LEIN, E. S., KNOWLES, J. A. & SESTAN, N. 2018. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. *Science*, 362.
- LINDSAY, S. J., XU, Y., LISGO, S. N., HARKIN, L. F., COPP, A. J., GERRELLI, D., CLOWRY, G. J., TALBOT, A., KEOGH, M. J., COXHEAD, J., SANTIBANEZ-KOREF, M. & CHINNERY, P. F. 2016. HDBR Expression: A Unique Resource for Global and Individual Gene Expression Studies during Early Human Brain Development. *Front Neuroanat*, 10, 86.
- LOVE, S. E., PERRY, A. E., IRONSIDE, J. W. E., BUDKA, H. E. & GREENFIELD, J. G. 2015. *Greenfield's neuropathology*.
- MARÍN-TEVA, J. L., ALMENDROS, A., CALVENTE, R., CUADROS, M. A. & NAVASCUÉS, J. 1998. Tangential migration of ameboid microglia in the developing quail retina: mechanism of migration and migratory behavior. *Glia*, 22, 31-52.
- MARÍN-TEVA, J. L., CALVENTE, R., CUADROS, M. A., ALMENDROS, A. & NAVASCUÉS, J. 1999. Circumferential migration of ameboid microglia in the margin of the developing quail retina. *Glia*, 27, 226-38.
- MARTÍN-ESTEBANÉ, M., NAVASCUÉS, J., SIERRA-MARTÍN, A., MARTÍN-GUERRERO, S. M., CUADROS, M. A., CARRASCO, M.-C. & MARÍN-TEVA, J. L. 2017. Onset of microglial entry into developing quail retina coincides with increased expression of active caspase-3 and is mediated by extracellular ATP and UDP. *PLOS ONE*, 12, e0182450.
- MENASSA, D. A. & GOMEZ-NICOLA, D. 2018. Microglial Dynamics During Human Brain Development. *Front Immunol*, 9, 1014.
- MITTELBRONN, M., DIETZ, K., SCHLUESENER, H. J. & MEYERMANN, R. 2001. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. *Acta Neuropathol*, 101, 249-55.
- MONIER, A., ADLE-BIASSETTE, H., DELEZOIDE, A. L., EVRARD, P., GRESSENS, P. & VERNEY, C. 2007. Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. *J Neuropathol Exp Neurol*, 66, 372-82.
- MONIER, A., EVRARD, P., GRESSENS, P. & VERNEY, C. 2006. Distribution and differentiation of microglia in the human encephalon during the first two trimesters of gestation. *J Comp Neurol*, 499, 565-82.

- NIKODEMOVA, M., KIMYON, R. S., DE, I., SMALL, A. L., COLLIER, L. S. & WATTERS, J. J. 2015. Microglial numbers attain adult levels after undergoing a rapid decrease in cell number in the third postnatal week. *J Neuroimmunol*, 278, 280-8.
- NOGALES, F. F. 1993. *The Human Yolk Sac and Yolk Sac Tumors*, Berlin, Heidelberg, Springer Berlin Heidelberg.
- O'RAHILLY, R. & MULLER, F. 2010. Developmental stages in human embryos: revised and new measurements. *Cells Tissues Organs*, 192, 73-84.
- OLMOS-ALONSO, A., SCHETTERS, S. T., SRI, S., ASKEW, K., MANCUSO, R., VARGAS-CABALLERO, M., HOLSCHER, C., PERRY, V. H. & GOMEZ-NICOLA, D. 2016.


  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. *Brain*, 139, 891-907.
- PAOLICELLI, R. C., BOLASCO, G., PAGANI, F., MAGGI, L., SCIANNI, M., PANZANELLI, P., GIUSTETTO, M., FERREIRA, T. A., GUIDUCCI, E., DUMAS, L., RAGOZZINO, D. & GROSS, C. T. 2011. Synaptic pruning by microglia is necessary for normal brain development. *Science*, 333, 1456-8.
- PARK, J. E., JARDINE, L., GOTTGENS, B., TEICHMANN, S. A. & HANIFFA, M. 2020. Prenatal development of human immunity. *Science*, 368, 600-603.
- PENZES, P., CAHILL, M. E., JONES, K. A., VANLEEUWEN, J.-E. & WOOLFREY, K. M. 2011. Dendritic spine pathology in neuropsychiatric disorders. *Nature Neuroscience*, 14, 285-293.
- PONT-LEZICA, L., BEUMER, W., COLASSE, S., DREXHAGE, H., VERSNEL, M. & BESSIS, A. 2014. Microglia shape corpus callosum axon tract fasciculation: functional impact of prenatal inflammation. *Eur J Neurosci*, 39, 1551-7.
- POPESCU, D. M., BOTTING, R. A., STEPHENSON, E., GREEN, K., WEBB, S., JARDINE, L., CALDERBANK, E. F., POLANSKI, K., GOH, I., EFREMOVA, M., ACRES, M., MAUNDER, D., VEGH, P., GITTON, Y., PARK, J. E., VENTO-TORMO, R., MIAO, Z., DIXON, D., ROWELL, R., MCDONALD, D., FLETCHER, J., POYNER, E., REYNOLDS, G., MATHER, M., MOLDOVAN, C., MAMANOVA, L., GREIG, F., YOUNG, M. D., MEYER, K. B., LISGO, S., BACARDIT, J., FULLER, A., MILLAR, B., INNES, B., LINDSAY, S., STUBBINGTON, M. J. T., KOWALCZYK, M. S., LI, B., ASHENBERG, O., TABAKA, M., DIONNE, D., TICKLE, T. L., SLYPER, M., ROZENBLATT-ROSEN, O., FILBY, A., CAREY, P., VILLANI, A. C., ROY, A., REGEV, A., CHÉDOTAL, A., ROBERTS, I., GÖTTGENS, B., BEHJATI, S., LAURENTI, E., TEICHMANN, S. A. & HANIFFA, M. 2019. Decoding human fetal liver haematopoiesis. *Nature*, 574, 365-371.


- RÉU, P., KHOSRAVI, A., BERNARD, S., MOLD, J. E., SALEHPOUR, M., ALKASS, K., PERL, S., TISDALE, J., POSSNERT, G., DRUID, H. & FRISÉN, J. 2017. The Lifespan and Turnover of Microglia in the Human Brain. *Cell Rep*, 20, 779-784.
- REZAIE, P. & MALE, D. 1999. Colonisation of the developing human brain and spinal cord by microglia: a review. *Microsc Res Tech*, 45, 359-82.
- ROBINSON, M. D., MCCARTHY, D. J. & SMYTH, G. K. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26, 139-40.
- SÁNCHEZ-LÓPEZ, A., CUADROS, M. A., CALVENTE, R., TASSI, M., MARÍN-TEVA, J. L. & NAVASCUÉS, J. 2004. Radial migration of developing microglial cells in quail retina: a confocal microscopy study. *Glia*, 46, 261-73.
- SCHINDELIN, J., ARGANDA-CARRERAS, I., FRISE, E., KAYNIG, V., LONGAIR, M., PIETZSCH, T., PREIBISCH, S., RUEDEN, C., SAALFELD, S., SCHMID, B., TINEVEZ, J. Y., WHITE, D. J., HARTENSTEIN, V., ELICEIRI, K., TOMANCAK, P. & CARDONA, A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods*, 9, 676-82.
- SCHWARZ, J. M., SHOLAR, P. W. & BILBO, S. D. 2012. Sex differences in microglial colonization of the developing rat brain. *J Neurochem*, 120, 948-63.
- SEKAR, A., BIALAS, A. R., DE RIVERA, H., DAVIS, A., HAMMOND, T. R., KAMITAKI, N., TOOLEY, K., PRESUMEY, J., BAUM, M., VAN DOREN, V., GENOVESE, G., ROSE, S. A., HANDSAKER, R. E., DALY, M. J., CARROLL, M. C., STEVENS, B., MCCARROLL, S. A. & SCHIZOPHRENIA WORKING GROUP OF THE PSYCHIATRIC GENOMICS, C. 2016. Schizophrenia risk from complex variation of complement component 4. *Nature*, 530, 177-183.
- SIERRA, A., ABIEGA, O., SHAHRAZ, A. & NEUMANN, H. 2013. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. *Front Cell Neurosci*, 7, 6.
- SIERRA, A., ENCINAS, J. M., DEUDERO, J. J., CHANCEY, J. H., ENIKOLOPOV, G., OVERSTREET-WADICHE, L. S., TSIRKA, S. E. & MALETIC-SAVATIC, M. 2010. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell*, 7, 483-95.
- SILBEREIS, J. C., POCHAREDDY, S., ZHU, Y., LI, M. & SESTAN, N. 2016. The Cellular and Molecular Landscapes of the Developing Human Central Nervous System. *Neuron*, 89, 248-68.
- SONESON, C. & ROBINSON, M. D. 2018. Bias, robustness and scalability in single-cell differential expression analysis. *Nature Methods*, 15, 255-261.


- SQUARZONI, P., OLLER, G., HOEFFEL, G., PONT-LEZICA, L., ROSTAING, P., LOW, D., BESSIS, A., GINHOUX, F. & GAREL, S. 2014. Microglia modulate wiring of the embryonic forebrain. *Cell Rep*, 8, 1271-9.
- STUART, T., BUTLER, A., HOFFMAN, P., HAFEMEISTER, C., PAPALEXI, E., MAUCK, W. M., 3RD, HAO, Y., STOECKIUS, M., SMIBERT, P. & SATIJA, R. 2019.


  Comprehensive Integration of Single-Cell Data. *Cell*, 177, 1888-1902 e21.
- SWINNEN, N., SMOLDERS, S., AVILA, A., NOTELAERS, K., PAESEN, R., AMELOOT, M., BRÔNE, B., LEGENDRE, P. & RIGO, J. M. 2013. Complex invasion pattern of the cerebral cortex bymicroglial cells during development of the mouse embryo. *Glia*, 61, 150-63.
- TAVIAN, M. & PEAULT, B. 2005. Embryonic development of the human hematopoietic system. *Int J Dev Biol*, 49, 243-50.
- TETREAULT, N. A., HAKEEM, A. Y., JIANG, S., WILLIAMS, B. A., ALLMAN, E., WOLD, B. J. & ALLMAN, J. M. 2012. Microglia in the Cerebral Cortex in Autism. *Journal of Autism and Developmental Disorders*, 42, 2569-2584.
- VANKRIEKELSVENNE, E., CHRZANOWSKI, U., MANZHULA, K., GREINER, T., WREE, A., HAWLITSCHKA, A., LLOVERA, G., ZHAN, J., JOOST, S., SCHMITZ, C., PONSAERTS, P., AMOR, S., NUTMA, E., KIPP, M. & KADDATZ, H. 2022.


  Transmembrane protein 119 is neither a specific nor a reliable marker for microglia. *Glia*, 70, 1170-1190.
- VELMESHEV, D., SCHIRMER, L., JUNG, D., HAEUSSLER, M., PEREZ, Y., MAYER, S., BHADURI, A., GOYAL, N., ROWITCH, D. H. & KRIEGSTEIN, A. R. 2019. Single-cell genomics identifies cell type-specific molecular changes in autism. *Science*, 364, 685-689.
- VERNEY, C., MONIER, A., FALLET-BIANCO, C. & GRESSENS, P. 2010. Early microglial colonization of the human forebrain and possible involvement in periventricular whitematter injury of preterm infants. *J Anat*, 217, 436-48.
- WAISE, S., PARKER, R., ROSE-ZERILLI, M. J. J., LAYFIELD, D. M., WOOD, O., WEST, J., OTTENSMEIER, C. H., THOMAS, G. J. & HANLEY, C. J. 2019. An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. *Sci Rep*, 9, 9580.


















## **SUPPLEMENTAL ITEMS**

## Index:

Figures S1 to S6

Tables S1, S2 and S4

## **SUPPLEMENTAL FIGURES**



**Figure S1**, *Related to figures 2*, *3 & 4*. (A, B) Microglia morphologies during development. (A) Microglial morphologies are amoeboid, proliferative, or migratory in the embryonic age (3-8 pcw) and (B), additional morphologies throughout fetal life (9-38 pcw) are seen such as clustered, phagocytic, and apoptotic. Scale bar: 50 μm. (C) Embryonic regional brain

proliferation and densities. Proliferative indices and IBA1<sup>+</sup> densities between brain regions (n=14). \*p<0.01, ns p>0.05. All data are shown as mean  $\pm$  SEM. (D, E) Delineation of anatomical boundaries in the developing cortex between 9 and 38 postconceptional weeks. (D) Nissl histochemistry of transient cortical zones. (E) Periodic-Acid Schiff/Alcian Blue histochemistry for marking the subplate in transient cortical zones. CP: cortical plate; GM: Grey matter; IZ: intermediate zone; MZ: marginal zone; PSP: presubplate; pcw: postconceptional week; SP: subplate; SPU: subplate upper portion; SPM: subplate middle portion; SPI: subplate inferior portion; SPL: subplate lower portion; SPr: subplate remnant; SVZ: subventricular zone; VZ: ventricular zone; VM: white matter. Scale bar: 100 µm.




Figure S2. Migratory microglial profile and phenotype during development, *Related to figures 2 & 3.* 

(A) Percentage of IBA1 cells migrating into the various transient zones (n=2 for each timepoint). At 9 pcw, the CP has no migrating microglia whilst most layers have substantial numbers of migrating cells. From 10-14 pcw, migrating cells are found in all layers and by 19 pcw, migrating cells can no longer be seen present in the MZ. (B) Type of migration in each transient layer (n=2 for each timepoint). Migration is radial and/or tangential depending on each layer across 9-19 pcw. *CP*: cortical plate; *IZ*: intermediate zone; *MZ*: marginal zone; *PSP*: presubplate; *pcw*: postconceptional week; *SP*: subplate;; *SVZ*: subventricular zone; *VZ*: ventricular zone.







Figure S3. TMEM119 expression during prenatal development, *Related to figure 3.* (A) IBA1 densities correlative positively with TMEM119 densities (n=10 cases between 10-28 pcw) (r=0.84, p<0.0047). (B) Deconvolution of signal showing that TMEM119 and IBA1 colocalise. (C) TMEM119<sup>+</sup> cells are not proliferative in the MZ (black arrows) in a representative 14 pcw neocortical column. Proliferation (non-microglial) is shown in the deeper layers (red arrows for the Ki67 signal). Scale bar: 100 μm. (D) TMEM119<sup>+</sup> cells co-express CD68 lysosomal marker in the MZ. Scale bar: 50 μm. *CP*: cortical plate; *MZ*: marginal zone; *SP*: subplate.




## Figure S4. Descriptive account of regional findings across development, Related to figures 2, 3 & 4.

(A) Proliferation of microglial cells is highest in the subplate region across gestation. Scale bar: 100 μm (B) Microglial cells invade the upper portion of the cortical plate by 25 pcw and spare it before that time. Scale bar: 100 μm (C) Ventral telencephalon microglia cluster around the internal and external capsules. These clusters increase during gestation and disappear by 28 pcw. Scale bar: 500 μm (D) Microglial hotspots can be seen in the intermediate zone during most of gestation and resolve by the 32<sup>nd</sup> pcw. Scale bar: 100 μm (E) Microglia are positive for MHCII. Scale bar: 75 μm (E) and towards the late third trimester, cluster in the ventricular zone. (F) Range of microglial morphologies from amoeboid to intermediate and ramified mature types can be seen in transient layers developmentally. Scale bar: 75 μm. *CP*: cortical plate; *GE*: ganglionic eminence; *IZ*: intermediate zone; *MZ*: marginal zone; *PSP*: presubplate; *pcw*: postconceptional week; *SP*: subplate;; *SVZ*: subventricular zone; *VZ*: ventricular zone.













Figure S5. Single-cell RNA-seq analysis, *Related to figure* 5. (A) Preliminary analysis identified a cluster enriched for erythrocyte (ERY) markers (e.g. HBG2, HBB). The single-nuclei dataset by (Cao et al. 2020) contributed most cells of this ERY cluster, suggesting that this cluster is a technical, method-specific artefact, albeit all datasets showed some degree of ERY. We removed the ERY cluster and re-clustered prior to our analysis of cycling proliferating cells. (B) Seurat clusters before the removal of the ERY cluster (left). Cycling and proliferating cell pattern was not affected. (C) 8 transcriptionally distinct clusters were identified in our integrated object. The heatmap displays the top 5 DEG of each cluster, as identified with the FindAllMarkers function (MAST). Several developmental homeostatic microglia were identified as well as several previously identified microglial subtypes (CPM, CAM, BAM). Of note, one cluster displayed markers not commonly associated with microglia with NPC-linked genes. which may suggest impurities in preparation; or capture a novel microglial subtype that restricts the progenitor pool. (D) Spatial distribution of gestational myeloid cells by original identity. *CS*: Carnegie stage; *GW/GA*: gestational week/age; *PCD*: postconceptional day; *PCW*: postconceptional week.










Figure S6. Tissue quality control and analysis, Related to Methods and Figures 1 & 4. (A) Reaction of microglia to hypoxia. Representative photomicrographs of microglia reactive to hypoxic-ischaemic injury in a 38 postconceptional term grey and white matters (Fetus 52 in table 7) and homeostatic microglial ramified morphology with a lower proliferation rate in the absence of hypoxic injury in a 38 postconceptional week case included in our study Note the amoeboid shape and higher proliferation rate compared to homeostatic microglia. Representative heatmap of proliferation and density along the cortical column. *SPr.* subplate remnant; *WM:* white matter. Scale bar: 50µm. (B) Deconvolution of signal in brightfield. Example of colour deconvolution in brightfield for proliferative microglia (IBA1/Ki67/Haematoxylin). Example of colour deconvolution in brightfield for cell death (Caspase 3/IBA1/Haematoxylin). Scale bar:  $10\mu$ m.(C) Migration analysis workflow: Layer selection, Deconvolution and Thresholded photomicrograph with particle selection according to a circularity criterion <0.3 for a migratory cell phenotype. The angle is recorded between the major axis of the cell and the layer plane with  $\alpha$ <45 for tangential and  $\alpha$ >45 for radial migrations. Tangential and radial microglial phenotypes. Scale bar:  $30\mu$ m. Figure S12. Heatmap analysis, Related to figure 4 & methods. (D) Workflow of image processing to obtain heatmaps from cortical columns. Columnar thickness measurements for heatmaps against age. CS: Carnegie stages.

Table S1. Data source characteristics, Related to figure 5 & methods.

	Source								
Age (pcw)	Bian et al. (2020)	Cao et al. (2020)	Fan et al. (2020)	Kracht et al. (2020)	# (of cells)				
3	9				9				
4	32				32				
5	24		1		25				
6	7		28		35				
7			17	2872	2889				
8	63		28	1926	2017				
9			11	2467	2478				
10			73	1806	1879				
11			31	767	798				
12			66		66				
13		1726		2175	3901				
14			64	876	940				
15			303	842	1145				
16		3032		842	3874				
17		458			458				
18		856	122		978				
19			149		149				
20			40		40				
21									
22			193		193				
23									
24			232		232				

\*pcw: postconceptional weeks

Case	GA (CS)	PCW	Sex	PMI (h)	BW (g)	Cause of Death	Histology
Embryo	5 (10)	Late 3 <sup>rd</sup>	F	3.67	n/a	Elective termination	Normal
Embryo	6 (12)	4	M	3	n/a	Elective termination	Normal
Embryo	6 (12)	4	F	3.92	n/a	Elective termination	Normal
Embryo	6 (12)	4	F	4.67	n/a	Elective termination	Normal
Embryo	7 (14)	5	M	7	n/a	Elective termination	Normal
Embryo	7 (14)	5	F	6.42	n/a	Elective termination	Normal
Embryo	7 (14)	5	M	n/k	n/a	Elective termination	Normal
Embryo	8 (16)	6	M	2.75	n/a	Elective termination	Normal
Embryo		6	F	2.73		Elective termination	Normal
	8 (16)				n/a 		
Embryo	9 (18)	7	M	5.25	n/a	Elective termination	Normal
Embryo	9 (18)	7	F	n/k	n/a	Elective termination	Normal
Embryo	10 (21)	8	М	1.25	n/a	Elective termination	Normal
Embryo	10 (21)	8	F	n/k	n/a	Elective termination	Normal
Embryo	11 (23)	9	М	n/k	n/k	Elective termination	Normal
Embryo	11 (23)	9	F	16.67	n/k	Elective termination	Normal
Fetus	12	10	F	16.67	n/k	Elective termination	Normal
Fetus	12	10	М	16.67	n/k	Elective termination	Normal
Fetus	12	10	n/k	3.33	n/k	Elective termination	Normal
Fetus	13	11	М	2	n/k	Termination of pregnancy	Normal
Fetus	13	11	М	n/k	n/k	Elective termination	Normal
Fetus	14	12	F	2.5	n/k	Elective termination	Normal
Fetus	14	12	F	120	10	Elective termination	Normal
Fetus	14	12	F	16.67	n/k	Elective termination	Normal
Fetus	15	13	М	n/k	n/k	Termination of pregnancy	Normal
Fetus	16	14	F	16.00	n/k	Elective termination	Normal
Fetus	16	14	М	n/k	n/k	Termination of pregnancy	Normal
Fetus	17	15	М	n/k	n/k	Termination of pregnancy	Normal

Fetus	17	15	F	n/k	n/k	Elective termination	Normal
Fetus	18	16	М	n/k	33	Elective termination	Normal
Fetus	18	16	М	16.67	n/k	Elective termination	Normal
Fetus	19	17	F	144	41	Elective termination	Normal
Fetus	19	17	М	n/k	n/k	Miscarriage	Normal
Fetus	20	18	М	16.67	n/k	Elective termination	
Fetus	21	19	М	48	65	Termination of pregnancy	Normal
Fetus	21	19	М	24	67	Miscarriage	Normal
Fetus	22	20	М	72	93	Miscarriage	Normal
Fetus	23	21	F	n/k	n/k	Termination of pregnancy	Normal
Fetus	25	23	М	48	121	Termination of pregnancy	Normal
Fetus	25	23	М	n/k	110	Intrauterine death	Normal
Fetus	26	24	F	n/k	125	Preterm birth	Normal
Fetus	27	25	F	6	n/k	Intrauterine death	Normal
Fetus	27	25	F	n/k	n/k	Preterm birth, defective placenta	Normal
Fetus	28	26	М	96	159	n/k	Normal
Fetus	28	26	М	n/k	n/k	n/k	Normal
Fetus	30	28	F	240	n/k	Maternal road accident/placental separation	Normal frontal histology
Fetus	34	32	М	144	312	Respiratory distress syndrome	Normal
Fetus	35	33	F	n/k	295	Pulmonary hypoplasia, preterm birth	Normal
Fetus	38	36	F	17	380	Preterm birth	Normal
Fetus	40	38	М	5	n/k	Perinatal asphyxia, cardiorespiratory arrest	Normal
Fetus	40	38	F	5	n/k	Placental disruption, in utero death	Normal
Fetus	40	38	М	n/k	370	Septicaemia, premature birth	Normal
Fetus†	40	38	М	72	356	Intrauterine death	Hypoxic injury

Total number of cases shown is n = 52. In total, 63 cases were assessed. † Only one hypoxic case is included in the table above for reference. Refer also to supplementary figure 1 for a representative example of excluded cases due to hypoxic injury to the area. *BW*: brain weight; *CS*: Carnegie stage; *F*: female; *GA*: gestational age; *M*: male; n/a: not applicable; n/k: not known; *PCW*: postconceptional week; *PMI*: post-mortem interval.

Case	Age (years)	Sex	PMI (h)	BW (g)	Cause of Death	Histology
Neonate	0.003*	F	n/k	390	Intrapartum asphyxia	Normal
Neonate	0.008*	F	n/k	400	SUDI	Normal
Neonate	0.01*	М	n/k	415	Intrapartum asphyxia	Normal
Neonate	0.02*	М	n/k	375	n/k	Normal
Neonate	0.03*	М	n/k	350	SUDI	Normal
Neonate	0.03*	F	n/k	335	SUDI	Normal
Neonate	0.05*	М	n/k	n/k	Respiratory arrest	Normal
Neonate	0.07*	F	n/k	395	Intrapartum asphyxia	Normal
Neonate	0.07*	M	n/k	465	SUDI	Normal
Neonate	0.08*	F	n/k	465	SUDI	Normal
Neonate	0.08*	F	n/k	525	SUDI	Normal
Infant	0.14*	F	n/k	535	Pneumonia	Normal
Infant	0.17*	М	n/k	530	SUDI	Normal
Infant	0.17*	М	n/k	555	SUDI	Normal
Infant	0.25*	М	72	598	SUDI	Normal
Infant	0.33*	М	n/k	840	SUDI	Normal
Infant	0.42*	F	n/k	485	SUDI	Normal
Infant	0.5*	М	n/k	885	SUDI	Normal
Infant	0.50*	М	n/k	n/k	n/k	Normal
Infant	0.92*	F	96	1008	SUDEP	Normal
Infant	0.92*	М	96	1288	Subdural haemorrhage	Normal
Child	1	М	48	1342	SUDEP	Normal
Child	1.5	F	n/k	1295	Aspiration, SUDEP	Normal
Child	2	M	96	1379	SUDEP	Normal
Adult	18	М	5	n/k	Car crash	Normal
Adult	25	М	53	1640	Suspension by ligature	Normal
Adult	25	М	81	1500	Road traffic collision	Normal

Adult	27	М	67	1540	Ischaemic heart disease	Normal
Adult	30	М	71	1670	n/k	Normal
Adult	35	F	44	1240	n/k	Normal
Adult	37	F	46	1290	Hepatic failure	Normal
Adult	40	М	48	1320	Pulmonary embolism	Normal
Adult	42	М	103	1560	Suspension by ligature	Normal
Adult	51	М	51	1460	Coronary artery atheroma	Normal
Adult	56	М	44	1500	Ischaemic heart disease	Normal
Adult	53	М	64	1520	Depressive episode	Normal
Adult	57	F	73	1320	Sudden death	Normal
Adult	59	F	50	1500	Cardiomegaly	Normal
Adult	60	М	52	1460	Ischaemic heart disease	Normal
Adult	66	М	48	1350	Hypertensive heart disease	Normal
Adult	71	F	41	1210	Ischaemic heart disease	Normal
Adult	74	F	41	1520	Pulmonary embolism	Normal
Adult	74	М	23	1350	Ischaemic heart disease	Normal
Adult	74	М	12	1600	Pulmonary embolism	Normal
Adult	75	F	24	1580	Ischaemic heart disease	Normal

Total number of cases shown is n = 45, total cases assessed is 71 (Excluded cases due to trauma, malformation, hypoxic injury to the area or loss of antigenicity). *BW:* brain weight; *F:* female; *M:* male; n/k: not known; *PMI:* post-mortem interval; *SUDEP*: sudden unexpected death in epilepsy; *SUDI*: sudden unexpected death in infancy; \**Age range in days for cases < 1 year:* (1 day - 335 days).